{"gene":"DYRK1B","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1999,"finding":"DYRK1B (MIRK) is a nuclear-localized serine/threonine kinase predominantly expressed in muscle and testis; a GFP fusion protein localizes mainly to the nucleus of transfected COS-7 cells, consistent with a bipartite nuclear localization motif in its sequence.","method":"GFP fusion protein transfection and fluorescence microscopy; sequence analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization experiment in cells with functional implication (nuclear kinase), single lab, one method","pmids":["9918863"],"is_preprint":false},{"year":2000,"finding":"DYRK1B (MIRK) is a downstream substrate of the MAPK pathway; activated ERKs down-regulate MIRK protein levels in vivo, and blocking MEK with PD98059 increases MIRK levels ~20-fold in colon carcinoma cells. Kinase-active MIRK (but not kinase-dead mutant) enables colon carcinoma cells to survive in serum-free medium.","method":"MEK inhibitor treatment, stable overexpression of wild-type vs. kinase-dead MIRK, serum-free growth assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase-dead controls used, multiple cell lines, single lab","pmids":["10910078"],"is_preprint":false},{"year":2002,"finding":"DYRK1B (MIRK) functions as a transcriptional co-activator of HNF1α by binding DCoHm (a dimerization cofactor of HNF1α), forming a MIRK–DCoHm–HNF1α complex; MIRK directly phosphorylates HNF1α at Ser249 within its CBP-binding domain. MKK3, an upstream stress-activated kinase, co-immunoprecipitates with MIRK and enhances its kinase activity and HNF1α transactivation.","method":"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, in vitro kinase assay, reporter assays with kinase-dead mutants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal binding methods, in vitro kinase assay, kinase-dead controls, functional reporter assays","pmids":["11980910"],"is_preprint":false},{"year":2002,"finding":"p38α and p38β (but not γ or δ) isoforms sequester DYRK1B (MIRK) in nuclear subnuclear complexes (~500–700 kDa) in a kinase-independent manner, preventing MIRK association with MKK3 and inhibiting its function as a transcriptional activator of HNF1α.","method":"Co-immunoprecipitation, size-exclusion FPLC fractionation, reporter assays, dominant-negative p38 constructs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, FPLC fractionation, functional reporter assays, isoform specificity tested, single lab with multiple orthogonal methods","pmids":["12384504"],"is_preprint":false},{"year":2003,"finding":"DYRK1B (MIRK) is induced by Rho-family GTPases (RhoA, Cdc42, and to a lesser extent Rac1) during skeletal muscle differentiation, and is required for myoblast fusion and induction of differentiation markers (myogenin, troponin T, myosin heavy chain); depletion by siRNA blocks these events.","method":"Promoter-reporter assays, transient expression of constitutively active GTPases, siRNA knockdown with differentiation marker readouts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional loss-of-function (siRNA), gain-of-function, multiple differentiation markers, multiple cell lines, single lab with orthogonal methods","pmids":["12902328"],"is_preprint":false},{"year":2003,"finding":"DYRK1B (MIRK) was identified as a binding partner of the Met adaptor protein RanBPM by yeast two-hybrid, confirmed by GST pulldown, Co-IP, and in vivo cross-linking; RanBPM inhibits MIRK kinase activity. Induction of MIRK inhibits cell migration and invasion, an effect attenuated by HGF or overexpressed RanBPM.","method":"Yeast two-hybrid, GST pulldown, Co-IP, in vivo cross-linking, stable inducible MIRK cell line, wounding and Transwell migration assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal binding methods, functional migration assays, kinase activity measurement, single lab","pmids":["14500717"],"is_preprint":false},{"year":2003,"finding":"Stable overexpression of DYRK1B (MIRK) enhances proteasome-dependent turnover of p27Kip1, cyclin D1, and p21Cip1 at the protein level without affecting p27 mRNA or promoter activity, indicating post-transcriptional regulation.","method":"Stable transfectants (wild-type vs. kinase-dead), proteasome inhibitor experiments, mRNA and promoter assays","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase-dead controls, proteasome inhibitor validation, single lab","pmids":["12455049"],"is_preprint":false},{"year":2004,"finding":"DYRK1B (MIRK) directly phosphorylates p27Kip1 at Ser10 in G0, stabilizing p27 and maintaining G0 arrest; phosphomimetic p27-S10D is more stable than wild-type, and non-phosphorylatable p27-S10A is less stable. MIRK co-localizes with nuclear p27 in G0 and does not induce p27 nuclear export. Depletion of MIRK by RNAi decreases p27 phosphorylation at Ser10 and increases G0→G1 entry.","method":"In vitro kinase assay, phosphomimetic/non-phosphorylatable mutants, RNAi knockdown, PCNA and p27 protein/stability assays, co-localization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay, mutant analysis, RNAi loss-of-function, replicated in multiple cell types","pmids":["15010468"],"is_preprint":false},{"year":2004,"finding":"DYRK1B (MIRK) binds cyclin D1 and phosphorylates it at Thr288 (in vivo and in vitro), promoting cyclin D1 destabilization; cyclin D1-T288A is more stable than wild-type. MIRK and GSK3β phosphorylate cyclin D1 additively at distinct sites. RNAi depletion of MIRK increases cyclin D1 protein without affecting mRNA.","method":"Co-immunoprecipitation, in vitro kinase assay, stable inducible MIRK transfectants, cyclin D1-T288A mutant, RNAi knockdown, GSK3β inhibitor LiCl","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay, binding demonstrated by Co-IP, phospho-site mutagenesis, RNAi, kinase inhibitor controls","pmids":["15075324"],"is_preprint":false},{"year":2004,"finding":"DYRK1B (MIRK) phosphorylates class II HDACs (HDAC5, MITR) at a conserved site within their nuclear localization region, reducing their nuclear accumulation in a dose- and kinase-dependent manner, thereby enabling MEF2C to activate the myogenin promoter during muscle differentiation. MIRK does not directly phosphorylate MEF2; the effect is indirect via HDAC phosphorylation.","method":"Co-expression studies, kinase-dead mutants, phosphomimetic MITR construct, reporter assays, subcellular localization of GFP-HDAC fusions, siRNA knockdown","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — kinase-dead controls, phosphomimetic mutants, localization experiments, functional reporter assays, single lab with multiple orthogonal methods","pmids":["15546868"],"is_preprint":false},{"year":2005,"finding":"DYRK1B (MIRK) phosphorylates p21Cip1 at Ser153 within its nuclear localization domain, causing a fraction of nuclear p21 to relocalize to the cytoplasm; cytoplasmic p21 blocks caspase 3 activation and promotes myoblast survival. Phosphomimetic p21-S153D localizes pan-cellularly and is more effective than wild-type at blocking caspase 3; non-phosphorylatable p21-S153A remains nuclear and has no survival effect.","method":"Overexpression and RNAi, GFP-p21 localization (fluorescence microscopy), phosphomimetic/non-phosphorylatable mutants, caspase 3 activation assays, colony-forming assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — phosphosite mutagenesis, localization experiments, functional caspase/survival assays, kinase-dead controls, single lab with multiple orthogonal methods","pmids":["15851482"],"is_preprint":false},{"year":2005,"finding":"DYRK1B (MIRK) is activated by signaling from Rac1 to MKK3; constitutively active Rac1QL activates MIRK through MKK3, which phosphorylates MIRK. Dominant-negative Rac1, dominant-negative MKK3, and MKK3 siRNA inhibit MIRK kinase activity. Endogenous Rac1 activates MIRK following E-cadherin ligation in confluent MDCK cells.","method":"Kinase activity assays, dominant-negative constructs, RNAi knockdown of MKK3, E-cadherin/Fc chimera engagement, Rac1 inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct kinase activity measurement, multiple genetic and pharmacological perturbations, endogenous signaling context confirmed, single lab","pmids":["16257974"],"is_preprint":false},{"year":2007,"finding":"DYRK1B (MIRK) is a novel downstream effector of oncogenic K-RAS in pancreatic cancer; K-RAS activates MIRK through Rac1→MKK3 signaling. Knockdown of K-RAS by three independent RNAi sequences, or of Rac1 by two independent RNAi sequences, or pharmacological Rac1 inhibition, or dominant-negative K-rasS17N all blocked MIRK activation.","method":"Reporter assays, RNAi knockdown (K-RAS, Rac1), dominant-negative K-ras, Rac1 inhibitor, kinase activity assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple independent RNAi sequences, pharmacological inhibitors, dominant-negative controls, consistent results across methods","pmids":["17671193"],"is_preprint":false},{"year":2008,"finding":"BCL2 and BCL-xL stabilize p27 in G0 via MIRK-mediated phosphorylation of p27 at Ser10; this G0 function requires BAX and BAK, as the effect is lost in bax−/−bak−/− cells. Re-expression of BAX in double-knockout cells restores Ser10-p27 phosphorylation, demonstrating that BAX/BAK modulate MIRK-dependent p27 stabilization.","method":"Genetic knockout cells (bax−/−bak−/−), BAX re-expression, phospho-specific p27 Ser10 immunoblotting, cell cycle analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in knockout cells, phospho-specific readout, single lab","pmids":["18818203"],"is_preprint":false},{"year":2009,"finding":"DYRK1B (MIRK) maintains viability of quiescent pancreatic cancer cells by increasing transcription of antioxidant genes (ferroxidase, SOD2, SOD3), thereby reducing intracellular ROS levels. Depletion of MIRK via inducible shRNA increases ROS, decreases colony-forming ability, and reduces viability; ectopic expression of SOD2 and ferroxidase rescues ROS levels in MIRK-depleted cells.","method":"Inducible shRNA knockdown, ROS measurement, antioxidant gene expression analysis, ectopic expression rescue, colony-forming assays, dye exclusion viability","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible knockdown with rescue experiment (ectopic antioxidant genes), multiple cell lines, ROS mechanistic link established","pmids":["19351855"],"is_preprint":false},{"year":2010,"finding":"Mutant RAS activates DYRK1B as part of a KRAS–DYRK1B network that mediates cell-autonomous negative regulation (antagonism) of autocrine Hedgehog (HH) signaling, interfering with Gli2 function and Gli3 processing, while simultaneously redirecting HH signaling toward a paracrine mode in pancreatic cancer.","method":"Genetic and cell biological studies in mutant RAS-expressing cells; RAS effector pathway analysis; Gli2/Gli3 processing assays","journal":"Nature structural & molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — established pathway cross-talk via functional assays, single lab, mechanism partially defined","pmids":["20512148"],"is_preprint":false},{"year":2010,"finding":"DYRK1B (MIRK) regulates colon cancer cell exit from quiescence by destabilizing cyclin D1 and cyclin D3, reducing CDK4/cyclin D activity and p130/Rb2 phosphorylation, thereby maintaining the quiescent state. Depletion of MIRK increases cyclin D1/D3 protein via slower turnover and allows cells to escape G0. Cyclin D1-T288A (Mirk phosphorylation site mutant), but not wild-type cyclin D1, shortens 5-FU-induced G1, confirming site-specific mechanism.","method":"RNAi knockdown, cyclin D1-T288A mutant expression, CDK4 activity assays, p130 phosphorylation, Hoechst/Pyronin Y G0 staining","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — phospho-site mutant rescue, multiple mechanistic readouts, single lab with orthogonal methods","pmids":["19542220"],"is_preprint":false},{"year":2012,"finding":"Cold-inducible RNA-binding protein CIRP directly binds DYRK1B/MIRK and inhibits its interaction with p27, resulting in decreased phosphorylation and destabilization of p27. CIRP does not affect DYRK1B binding to cyclin D1 but inhibits DYRK1B-mediated phosphorylation of cyclin D1, leading to cyclin D1 stabilization. CIRP and DYRK1B co-localize in the nucleus of undifferentiated spermatogonia.","method":"Co-immunoprecipitation (direct CIRP–DYRK1B binding), siRNA knockdown, protein stability assays, G0 fraction analysis, immunofluorescence co-localization in spermatogonia","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding confirmed by Co-IP, knockdown with consistent phenotype in vitro and in vivo (knockout mice), substrate-specific effects dissected","pmids":["22711815"],"is_preprint":false},{"year":2014,"finding":"DYRK1B inhibits SHH and Wnt signaling pathways and enhances adipogenesis; the disease-associated R102C allele shows gain-of-function activity, potentiating these effects. DYRK1B also promotes expression of glucose-6-phosphatase (a key gluconeogenic enzyme).","method":"Functional characterization in patient-derived cell lines and model systems; pathway reporter assays; gene expression analysis; R102C gain-of-function mutant characterization","journal":"The New England journal of medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional pathway assays with mutant characterization, single study with multiple pathway readouts","pmids":["24827035"],"is_preprint":false},{"year":2014,"finding":"Using the selective DYRK1B inhibitor AZ191, it was demonstrated that DYRK1B phosphorylates cyclin D1 at Thr286 (not Thr288 as previously reported) in vitro and in cells, and this is independent of GSK3β. In PANC-1 and HEK293 cells, DYRK1B drives Thr286 phosphorylation and proteasome-dependent cyclin D1 turnover; AZ191 or DYRK1B RNAi abolishes this, while GSK3β inhibitors or GSK3β RNAi do not. DYRK1B also promotes p21CIP1 and p27KIP1 expression.","method":"In vitro kinase assay, phospho-specific immunoblot, mass spectrometry, selective small-molecule inhibitor (AZ191), DYRK1B RNAi, GSK3β RNAi and inhibitors","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay + MS phosphosite identification + selective inhibitor + RNAi, multiple orthogonal approaches in one study","pmids":["24134204"],"is_preprint":false},{"year":2014,"finding":"DYRK1B (MIRK) is upregulated several-fold by mTOR inhibitors (RAD001, WYE354, rapamycin) via CREB-mediated transcription; CREB binds two sites in the MIRK promoter and one site in exon 4. Depletion of CREB reduces MIRK expression; depletion of mTOR increases it. Activated Akt–ER construct blocks the mTOR-inhibitor-induced increase in MIRK mRNA.","method":"mTOR inhibitor treatment, CREB ChIP/reporter assays, siRNA knockdown of CREB and mTOR, inducible Akt-ER construct","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter binding, siRNA knockdown, pathway manipulation, single lab","pmids":["24590896"],"is_preprint":false},{"year":2014,"finding":"DYRK1B (MIRK) in differentiated skeletal muscle (fast-twitch fibers) and cycling myoblasts reduces ROS by maintaining expression of antioxidant genes; pharmacological MIRK kinase inhibition or depletion increases ROS in both C2C12 myoblasts and differentiated myotubes. MIRK protein translocates from nucleus (cycling myoblasts) to cytoplasm (differentiating myoblasts and mature fast-twitch fibers).","method":"MIRK kinase inhibitor treatment, inducible shRNA, ROS measurement, immunofluorescence and cell fractionation for localization, antioxidant gene expression","journal":"Genes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by fractionation and imaging with functional consequence, inhibitor and knockdown convergence, single lab","pmids":["24955215"],"is_preprint":false},{"year":2015,"finding":"DYRK1B is a substrate of ERK2: ERK2 phosphorylates DYRK1B at Ser421 in vitro; selective ERK1/2 pathway activation increases p-S421 in cells. DYRK1B also trans-autophosphorylates at S421 in vitro and in cells. A catalytically inactive DYRK1B(D239A) mutant has very low p-S421 in cells, increased by KRAS(G12V). S421 phosphorylation contributes to DYRK1B kinase activity. DYRK1B is activated by cis-autophosphorylation on Y273 during translation.","method":"In vitro kinase assay with recombinant ERK2, phospho-specific immunoblot, selective MEK inhibitors, pathway-selective activation constructs, kinase-dead DYRK1B mutants, KRAS(G12V) expression","journal":"Cellular and molecular life sciences : CMLS","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, multiple mutants, selective inhibitors, consistent in vitro and in-cell results","pmids":["26346493"],"is_preprint":false},{"year":2015,"finding":"DYRK1B interacts with the tumor suppressor NKX3.1 via the DYRK1B kinase domain and phosphorylates NKX3.1 at Ser185 in vitro, promoting NKX3.1 degradation; this residue is critical for NKX3.1 steady-state turnover. Small-molecule DYRK1B inhibitors prolonged NKX3.1 half-life.","method":"siRNA kinase screen, Co-IP (kinase domain interaction), in vitro kinase assay, phospho-specific site (S185) mutagenesis, protein stability/half-life assays, small-molecule inhibitors","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro kinase assay, binding domain defined, phosphosite mutagenesis, inhibitor validation, multiple methods","pmids":["25777618"],"is_preprint":false},{"year":2017,"finding":"DYRK1B mediates Hedgehog (Hh)-induced mTOR/AKT activation: Hh signaling induces DYRK1B protein expression in fibroblasts, which then activates the mTOR/AKT kinase signaling arm. DYRK1B exerts negative feedback on canonical SMO-mediated Hh/GLI signaling while providing positive feed-forward regulation by promoting AKT-mediated GLI stability.","method":"Genetic and pharmacological inhibition of DYRK1B, Hh pathway stimulation, AKT/mTOR phosphorylation readouts, GLI1 expression assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and chemical inhibition with pathway readouts, single lab, mechanism partially defined","pmids":["27903983"],"is_preprint":false},{"year":2017,"finding":"DYRK1B missense mutations (H90P and R102C) affecting the DYRK homology (DH) box do not alter the specific catalytic activity of mature DYRK1B but cause accumulation of the mutant protein in detergent-insoluble cytoplasmic aggregates in an underphosphorylated (on tyrosine) form. Mutant DYRK1B shows enhanced binding to co-chaperone CDC37 and greater sensitivity to the HSP90 inhibitor ganetespib, indicating impaired chaperone-dependent maturation.","method":"Cellular kinase activity assays, detergent fractionation, phospho-tyrosine immunoblotting, HSP90 inhibitor sensitivity, Co-IP with CDC37","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical assays, single lab, mechanism of misfolding defined","pmids":["28743892"],"is_preprint":false},{"year":2018,"finding":"DYRK1B mediates Hedgehog-induced microtubule (MT) acetylation by inhibiting GSK3β through phosphorylation of GSK3β Serine 9, which suppresses HDAC6 activity (a major tubulin deacetylase), resulting in increased acetylated MTs. This DYRK1B-dependent MT acetylation facilitates mitochondrial transport, mesenchymal cell polarization, and directed cell migration.","method":"Hh pathway stimulation, DYRK1B knockdown/inhibition, GSK3β S9 phospho-specific immunoblot, HDAC6 activity assay, MT acetylation assays, mitochondrial transport and migration assays","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phospho-specific substrate readout, functional downstream consequence, single lab","pmids":["30317528"],"is_preprint":false},{"year":2018,"finding":"WDR68 (DCAF7) is required for normal protein levels of DYRK1B (and DYRK1A); WDR68 knockout in C2C12 and HeLa cells reduces DYRK1B protein levels without affecting mRNA, and proteasome inhibition does not restore DYRK1B, suggesting WDR68 is required for proper kinase stabilization/maturation rather than preventing proteasomal degradation.","method":"Engineered knockout cell lines, Western blotting, RT-PCR, proteasome inhibitor treatment, WDR68 overexpression","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout, multiple negative controls, single lab","pmids":["30496304"],"is_preprint":false},{"year":2020,"finding":"DYRK1B is recruited to laser-microirradiated DNA double-strand break (DSB) sites, and its kinase activity is required for DSB-induced transcriptional silencing on active chromatin and for efficient DNA repair. DYRK1B phosphorylates the histone methyltransferase EHMT2, enforcing its DSB accumulation, establishing a DYRK1B–EHMT2 axis. Genetic inactivation of DYRK1B or its kinase activity attenuates DSB-induced gene silencing and impairs DNA repair.","method":"Kinome-wide chemical screen, laser micro-irradiation, live-cell imaging of DYRK1B recruitment, genetic inactivation (knockout/kinase-dead), global transcription shutdown rescue, EHMT2 phosphorylation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — live imaging of recruitment, kinase-dead mutant, genetic knockout, substrate phosphorylation, rescue experiments, multiple orthogonal methods","pmids":["32611815"],"is_preprint":false},{"year":2021,"finding":"DYRK1B is required for full suppression of rDNA (ribosomal DNA) transcription following DSBs, exhibiting robust nucleolar accumulation after laser micro-irradiation. DYRK1B inactivation leads to sustained nucleolar transcription after DSBs, impaired rDNA DSB repair, and reduced rDNA copy number maintenance. This nucleolar DSB response can be uncoupled from ATM-mediated DSB signaling.","method":"Targeted rDNA DSBs, laser micro-irradiation, chemical inhibition and genetic inactivation of DYRK1B, rRNA synthesis assays, rDNA copy number analysis, cell sensitivity assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — targeted rDNA DSBs, chemical and genetic inhibition, multiple functional readouts, single lab with orthogonal methods","pmids":["33469661"],"is_preprint":false},{"year":2022,"finding":"DYRK1B promotes hepatic lipogenesis by activating mTORC2 in a kinase-independent fashion. Dyrk1b overexpression in mouse liver enhanced de novo lipogenesis, fatty acid uptake, triacylglycerol secretion, and caused NASH; the Dyrk1b-induced NASH was fully rescued when mTORC2 was genetically disrupted. The resulting elevated diacylglycerol activated PKCε and led to IRKT1150 phosphorylation, impairing hepatic insulin signaling.","method":"Liver-specific AAV-mediated overexpression, genetic mTORC2 disruption (rescue experiment), Dyrk1b knockdown, lipogenesis assays, PKCε and IR phosphorylation assays, in vivo mouse models","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue (mTORC2 KO fully rescues), kinase-independent mechanism established, multiple in vivo and in vitro readouts","pmids":["34855620"],"is_preprint":false},{"year":2022,"finding":"DYRK1B directly binds STAT3 and increases its phosphorylation and nuclear accumulation, contributing to downregulation of PGC-1α and impaired mitochondrial bioenergetics in cardiac hypertrophy and heart failure. Cardiac-specific DYRK1B overexpression causes cardiac dysfunction; DYRK1B knockout mitigates TAC-induced cardiac hypertrophy and heart failure.","method":"Transgenic and knockout mice (TAC model), Co-IP (DYRK1B–STAT3 binding), STAT3 phosphorylation and nuclear accumulation assays, PGC-1α expression, mitochondrial functional analysis, specific inhibitors","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic and KO models, direct binding by Co-IP, phosphorylation and localization readouts, inhibitor validation","pmids":["35235343"],"is_preprint":false},{"year":2022,"finding":"DYRK1B maturation requires the CMGC insert and adjacent sequences; human DYRK1B autophosphorylation is severely compromised in bacterial cell-free systems (unlike DYRK1A or zebrafish/Xenopus DYRK1B orthologs), and the differential folding is largely due to divergent C-terminal lobe sequences. DYRK1B's mature kinase domain has lower thermal stability than DYRK1A.","method":"Bacterial expression systems (cell-free), autophosphorylation assays, thermal stability assays, domain comparison across species, heat challenge in vitro and in cells","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution and biochemical assays, single lab, ortholog comparison but limited to single study","pmids":["35165364"],"is_preprint":false},{"year":2023,"finding":"DYRK1B phosphorylates FOXO1 at Ser329 to regulate its cytoplasmic/nuclear localization; DYRK1B inhibition enhances nuclear FOXO1 retention (by blocking Ser329 phosphorylation), promoting Treg differentiation and suppressing Th1/Th17 differentiation in CD4+ T cells.","method":"DYRK1B inhibitor treatment, FOXO1 phospho-specific assays (Ser329), T cell differentiation assays (FACS), Treg/Th1/Th17 marker analysis, murine CHS model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phospho-specific substrate site identified, in vitro and in vivo validation, single lab","pmids":["37120440"],"is_preprint":false},{"year":2024,"finding":"DYRK1B downregulates the phagocytosis checkpoint 'don't eat me' signal CD24 on pancreatic cancer cells; genetic ablation or pharmacological inhibition of DYRK1B strongly attracts tumoricidal macrophages and enhances tumor cell phagocytosis. Tumor cells lacking DYRK1B barely expand in vivo despite growing rapidly in culture.","method":"Transplantation and autochthonous mouse PDAC models, genetic Dyrk1b loss, pharmacological inhibition, co-culture experiments, CD24 surface expression analysis, phagocytosis assays, bulk mRNA sequencing and proteomics (secretomics)","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic and pharmacological models, direct mechanistic link to CD24 and phagocytosis, multiple orthogonal approaches","pmids":["38834297"],"is_preprint":false},{"year":2024,"finding":"DYRK1B is a novel substrate of and negative feedback regulator on the transcription factor RFX7: DYRK1B is induced by cytostatic drugs (Actinomycin D, Doxorubicin) via p53-dependent activation of RFX7; DYRK1B physically interacts with RFX7 and counteracts its p53-mediated activation in a catalytic-activity-dependent manner, establishing a negative feedback loop.","method":"Drug treatment in multiple cancer cell lines, p53-dependent induction assays, Co-IP (DYRK1B–RFX7 interaction), kinase-dead DYRK1B mutants, DYRK1 small-molecule inhibitors","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP binding, kinase-dead controls, inhibitor validation, single lab","pmids":["41888523"],"is_preprint":false},{"year":2025,"finding":"DYRK1B promotes hepatic gluconeogenesis and glucose intolerance by interacting with and phosphorylating FOXO1 primarily at Thr467/Ser468, which is essential for FOXO1 nuclear localization; additionally, DYRK1B inhibits AKT-mediated FOXO1 phosphorylation at Thr24 and Ser256, enhancing FOXO1 nuclear retention and gluconeogenic gene expression. Liver-specific Dyrk1b conditional knockout mice are protected from diet-induced hyperglycemia.","method":"In vivo/in vitro kinase assays, liver-specific Dyrk1b cKO mice, Co-IP (DYRK1B–FOXO1), phospho-specific immunoblotting at FOXO1 sites, gluconeogenesis gene expression assays, AZ191 pharmacological inhibitor","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro and in vivo kinase evidence, conditional KO rescue, phospho-site–specific analysis, multiple orthogonal methods","pmids":["40287828"],"is_preprint":false},{"year":2025,"finding":"The CMGC insert sequence and two adjacent proline residues (P332/P333 in DYRK1B) are critical for DYRK1B tyrosine autophosphorylation and maturation; mutation of either proline impairs autophosphorylation and nuclear localization. Substitution of the DYRK1B CMGC insert with that of DYRK1A rescues the maturation defect. The pathogenic R349W mutation associated with monogenic obesity/type 2 diabetes also disrupts autophosphorylation.","method":"Domain swaps, point mutations, autophosphorylation assays, nuclear localization studies, X-ray crystallography structural context","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — domain swap rescue experiments, multiple point mutants, functional and localization readouts, disease-variant correlation","pmids":["41444824"],"is_preprint":false},{"year":2025,"finding":"DYRK1B crystal structure was solved in complex with the inhibitor AZ191, revealing features in the hinge-binding region and differential accessibility of the catalytic lysine compared to DYRK1A that are pivotal for kinase selectivity.","method":"X-ray crystallography, quantum-mechanical and molecular-dynamics analyses, enzyme inhibition assays, cellular target engagement","journal":"International journal of biological macromolecules","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure determination with functional validation, multiple biophysical and biochemical methods","pmids":["41061777"],"is_preprint":false},{"year":2025,"finding":"DYRK1B inhibition reduces STAT3 phosphorylation in leukocytes, leading to decreased integrin activation, reduced leukocyte adhesion/migration, suppression of pro-inflammatory cytokines and eicosanoids, induction of apoptosis in neutrophils, and increased efferocytosis; this DYRK1B/STAT3 axis is identified as a regulator of inflammatory resolution.","method":"Small-molecule DYRK1B inhibitor (C81), STAT3 phosphorylation assays, leukocyte adhesion/migration assays, cytokine measurements, murine psoriasis and choroidal neovascularization models","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition, phospho-specific substrate readout, in vivo models, single lab","pmids":["39985685"],"is_preprint":false},{"year":2024,"finding":"DYRK1B promotes proteasomal degradation of WBP2 through enhanced WBP2 ubiquitylation (kinase-activity-dependent), thereby impairing hepatic insulin signaling; restoration of WBP2 partially rescues DYRK1B overexpression-induced glucose intolerance in vivo.","method":"Dyrk1b overexpression/knockout in mice, quantitative proteomics, ubiquitylation assays, WBP2 rescue experiments, kinase-dead mutant controls","journal":"Heliyon","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomics discovery, ubiquitylation assay, in vivo rescue, kinase-dead controls, single lab","pmids":["39296215"],"is_preprint":false},{"year":2021,"finding":"DYRK1B upregulates 4E-BP1 (a translational inhibitor) in C2C12 myofibers as a post-transcriptional target; CRISPR/Cas9 knockout of Dyrk1b in zebrafish also identifies 4E-BP1 as a downstream target in vivo. 4E-BP1 enhances autophagy and mediates Dyrk1b's effects on skeletal muscle differentiation. The disease-associated Dyrk1bR102C mutation impairs muscle differentiation via excessive 4E-BP1/autophagy activation, rescued by reduction of autophagic flux.","method":"Untargeted proteomics (C2C12), CRISPR/Cas9 zebrafish knockout, siRNA knockdown and overexpression in C2C12, autophagy flux assays, rescue experiments","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomics discovery confirmed in vivo (zebrafish KO), functional rescue, multiple genetic approaches, single lab","pmids":["34752933"],"is_preprint":false},{"year":2025,"finding":"DYRK1B kinase inhibition by AZ191 reduces total small extracellular vesicle (EV) number and alters intracellular distribution of the EV marker CD63, suggesting DYRK1B plays a role in EV trafficking. DYRK1B knockdown confirms the EV reduction effect.","method":"High-throughput nanoscale flow cytometry, kinase inhibitor screen (AZ191), siRNA knockdown, CD63 intracellular distribution imaging","journal":"Nanoscale","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pharmacological inhibitor plus knockdown, mechanistic pathway not fully resolved","pmids":["40063071"],"is_preprint":false}],"current_model":"DYRK1B (MIRK) is a nuclear/cytoplasmic serine/threonine kinase that is activated by cis-autophosphorylation on Y273 during translation (requiring the CMGC insert and adjacent prolines), further regulated by MKK3-mediated phosphorylation downstream of Rac1 and K-RAS, and by ERK2-mediated phosphorylation at S421; it maintains cellular quiescence by directly phosphorylating and stabilizing p27Kip1 (Ser10), destabilizing cyclin D1 (Thr286) and cyclin D3, phosphorylating and redistributing p21Cip1 (Ser153) to the cytoplasm for anti-apoptotic function, and phosphorylating class II HDACs to relieve MEF2-mediated transcription during myogenesis; it promotes cell survival by upregulating antioxidant genes (SOD2, SOD3, ferroxidase) to reduce ROS, binds STAT3 to increase its phosphorylation and nuclear accumulation, phosphorylates FOXO1 (Thr467/Ser468) to regulate gluconeogenesis and T-cell differentiation, phosphorylates NKX3.1 (Ser185) to promote its degradation, activates mTORC2 in a kinase-independent manner to drive hepatic lipogenesis, interacts with and negatively regulates the transcription factor RFX7 downstream of p53, mediates DSB-induced transcriptional silencing via phosphorylation of EHMT2, and controls rDNA transcription suppression and repair after nucleolar DSBs."},"narrative":{"mechanistic_narrative":"DYRK1B (MIRK) is a dual-specificity nuclear/cytoplasmic serine/threonine kinase that enforces cellular quiescence and survival across muscle, cancer, and metabolic tissues [PMID:9918863, PMID:15010468, PMID:19351855]. Its activation requires cis-autophosphorylation on Y273 during translation, a maturation step uniquely dependent on the CMGC insert and adjacent prolines P332/P333 and on the co-chaperone factors WDR68/DCAF7 and HSP90/CDC37 [PMID:26346493, PMID:41444824, PMID:28743892, PMID:30496304]; activity is further tuned by an upstream Rac1→MKK3 module activated downstream of oncogenic K-RAS and by ERK2-mediated phosphorylation at S421 [PMID:16257974, PMID:17671193, PMID:26346493]. A central function is post-transcriptional control of the cell-cycle machinery: DYRK1B phosphorylates p27Kip1 at Ser10 to stabilize it and maintain G0 arrest, phosphorylates cyclin D1 (Thr286) and cyclin D3 to drive their proteasomal turnover, and phosphorylates p21Cip1 at Ser153 to redistribute it to the cytoplasm where it blocks caspase-3 activation and promotes survival [PMID:15010468, PMID:19542220, PMID:24134204, PMID:15851482]. In skeletal muscle it drives differentiation by phosphorylating class II HDACs to relieve MEF2-dependent transcription, and supports quiescent-cell viability by upregulating antioxidant genes (SOD2, SOD3, ferroxidase) to suppress ROS [PMID:15546868, PMID:12902328, PMID:19351855, PMID:24955215]. DYRK1B also phosphorylates additional substrates to control their stability or localization—NKX3.1 (Ser185, degradation), FOXO1 (Thr467/Ser468, nuclear retention and gluconeogenesis), and EHMT2 during the DNA damage response—and is recruited to DNA double-strand breaks and nucleoli to enforce transcriptional silencing and rDNA repair [PMID:25777618, PMID:40287828, PMID:32611815, PMID:33469661]. In metabolic disease it promotes hepatic lipogenesis through kinase-independent activation of mTORC2 and gluconeogenesis via FOXO1, with liver-specific knockout protecting against hyperglycemia [PMID:34855620, PMID:40287828], and it binds STAT3 to amplify its phosphorylation and nuclear accumulation in cardiac hypertrophy and inflammation [PMID:35235343, PMID:39985685]. Gain-of-function coding variants (R102C, R349W) cause a monogenic metabolic syndrome of central obesity and type 2 diabetes, acting through impaired maturation and altered downstream signaling [PMID:24827035, PMID:41444824].","teleology":[{"year":1999,"claim":"Established DYRK1B's basic identity and subcellular address: it is a nuclear serine/threonine kinase enriched in muscle and testis, defining the tissues where its biology would later be dissected.","evidence":"GFP-fusion localization in COS-7 cells and sequence analysis","pmids":["9918863"],"confidence":"Medium","gaps":["No substrate or pathway identified","Single localization method in one cell type"]},{"year":2000,"claim":"Placed DYRK1B downstream of MAPK signaling and assigned it a survival function, showing kinase-active MIRK lets carcinoma cells survive serum withdrawal while ERK activity suppresses MIRK protein.","evidence":"MEK inhibitor treatment and wild-type vs. kinase-dead overexpression with serum-free survival assays","pmids":["10910078"],"confidence":"Medium","gaps":["Mechanism of ERK-dependent downregulation not defined","Survival effector substrates unknown"]},{"year":2002,"claim":"Resolved the proximal regulatory inputs to MIRK by identifying MKK3 as an activating upstream kinase and p38α/β as kinase-independent sequestering inhibitors, and defined HNF1α (Ser249) as a transcriptional substrate.","evidence":"Yeast two-hybrid, Co-IP/FPLC fractionation, in vitro kinase and reporter assays","pmids":["11980910","12384504"],"confidence":"High","gaps":["Physiological context of HNF1α phosphorylation not established","Stoichiometry of p38 sequestration unclear"]},{"year":2003,"claim":"Defined DYRK1B as a Rho-GTPase-induced driver of myoblast differentiation and a brake on cell migration/invasion regulated by the Met adaptor RanBPM, linking it to both differentiation and motility control.","evidence":"Constitutively active GTPase expression, siRNA with differentiation markers, yeast two-hybrid/Co-IP and migration assays","pmids":["12902328","14500717"],"confidence":"High","gaps":["Direct substrates driving fusion not identified at this stage","How RanBPM inhibits kinase activity unresolved"]},{"year":2004,"claim":"Established the core quiescence mechanism: DYRK1B directly phosphorylates p27Kip1 (Ser10) to stabilize it, phosphorylates cyclin D1 to destabilize it, and phosphorylates class II HDACs to relieve MEF2-driven myogenesis, converting earlier correlative survival/differentiation roles into defined substrate-level events.","evidence":"In vitro kinase assays, phospho-site mutagenesis, RNAi, and reporter/localization assays","pmids":["15010468","15075324","15546868","12455049"],"confidence":"High","gaps":["Exact cyclin D1 site (Thr286 vs Thr288) later revised","How a single kinase coordinates opposite stabilizing/destabilizing outcomes unexplained"]},{"year":2005,"claim":"Extended the survival program to p21Cip1: DYRK1B phosphorylates p21 at Ser153 to drive cytoplasmic relocalization where it blocks caspase-3, and traced upstream activation to a Rac1→MKK3 cascade engaged by E-cadherin ligation.","evidence":"Phosphomimetic mutants, GFP-p21 localization, caspase assays, dominant-negative Rac1/MKK3 and kinase activity assays","pmids":["15851482","16257974"],"confidence":"High","gaps":["Endogenous trigger of the survival pathway in tumors not defined","Link between cell contact and kinase activation incompletely mapped"]},{"year":2007,"claim":"Connected DYRK1B to oncogenic transformation by showing K-RAS activates it through Rac1→MKK3 in pancreatic cancer, establishing it as a RAS effector relevant to therapy.","evidence":"Multiple independent RNAi sequences, dominant-negative K-ras, Rac1 inhibitor, kinase activity assays","pmids":["17671193"],"confidence":"High","gaps":["Whether RAS-driven quiescence is reversible therapeutically not addressed","Downstream effectors in tumors not fully enumerated"]},{"year":2008,"claim":"Linked apoptotic machinery to quiescence control, showing BCL2/BCL-xL stabilize p27 via MIRK-mediated Ser10 phosphorylation in a BAX/BAK-dependent manner.","evidence":"bax−/−bak−/− knockout cells with BAX re-expression and phospho-specific p27 immunoblotting","pmids":["18818203"],"confidence":"Medium","gaps":["Molecular link between BAX/BAK and MIRK activity unresolved","Single lab/genetic system"]},{"year":2009,"claim":"Defined the survival mechanism of quiescent tumor cells: DYRK1B upregulates antioxidant genes (SOD2, SOD3, ferroxidase) to lower ROS, with ectopic antioxidant rescue confirming causality.","evidence":"Inducible shRNA, ROS measurement, antioxidant gene expression, and ectopic-expression rescue","pmids":["19351855"],"confidence":"High","gaps":["Transcriptional mechanism for antioxidant gene induction not defined","Direct substrate mediating gene expression unknown"]},{"year":2010,"claim":"Consolidated the quiescence cell-cycle model (cyclin D1/D3 destabilization maintaining G0) and connected DYRK1B to Hedgehog pathway antagonism downstream of mutant RAS.","evidence":"RNAi, cyclin D1-T288A rescue, CDK4/p130 readouts, and Gli2/Gli3 processing assays","pmids":["19542220","20512148"],"confidence":"High","gaps":["Mechanism of HH antagonism only partially defined","How quiescence couples to paracrine HH redirection unclear"]},{"year":2012,"claim":"Identified CIRP as a substrate-selective regulator that binds DYRK1B and uncouples its p27 versus cyclin D1 activities, revealing combinatorial control of the quiescence program.","evidence":"Co-IP, siRNA, stability assays, and co-localization in spermatogonia","pmids":["22711815"],"confidence":"High","gaps":["Structural basis of substrate-selective inhibition unknown","Physiological role in spermatogonia not fully tested"]},{"year":2014,"claim":"Linked DYRK1B to human disease and metabolism: a gain-of-function R102C allele causes a monogenic syndrome of obesity and diabetes, enhancing adipogenesis, suppressing SHH/Wnt, and promoting gluconeogenic gene expression; selective inhibitor and MS work corrected the cyclin D1 site to Thr286 (GSK3β-independent) and CREB was shown to drive MIRK transcription upon mTOR inhibition.","evidence":"Patient-derived cells and reporter assays; AZ191 inhibitor with MS phospho-mapping; CREB ChIP/reporter and siRNA","pmids":["24827035","24134204","24590896","24955215"],"confidence":"High","gaps":["Mechanism converting R102C to gain-of-function not yet defined here","How adipogenic and cell-cycle roles integrate metabolically unclear"]},{"year":2015,"claim":"Defined DYRK1B activation biochemistry—cis-autophosphorylation on Y273 during translation plus ERK2-mediated and trans-autophosphorylation at S421 contributing to activity—and added NKX3.1 (Ser185) as a degradation substrate.","evidence":"In vitro kinase assays with recombinant ERK2, kinase-dead mutants, KRAS(G12V), Co-IP and phospho-site mutagenesis","pmids":["26346493","25777618"],"confidence":"High","gaps":["Relative contribution of each phospho-input in vivo not quantified","Structural basis of co-translational maturation not yet resolved"]},{"year":2017,"claim":"Mechanistically explained disease alleles and expanded Hedgehog signaling roles: DH-box mutations (H90P/R102C) impair chaperone-dependent maturation causing cytoplasmic aggregates, and DYRK1B mediates Hh-induced mTOR/AKT activation with dual feedback on GLI.","evidence":"Detergent fractionation, phospho-tyrosine immunoblot, CDC37 Co-IP, HSP90 inhibitor sensitivity; Hh stimulation with AKT/mTOR readouts","pmids":["28743892","27903983"],"confidence":"Medium","gaps":["Aggregation phenotype not linked to in vivo disease tissue","Direct DYRK1B substrate in Hh→mTOR axis unknown"]},{"year":2018,"claim":"Established cytoskeletal and chaperone-network roles: DYRK1B phosphorylates GSK3β-Ser9 to suppress HDAC6 and increase microtubule acetylation, and WDR68/DCAF7 is required for DYRK1B protein stabilization/maturation.","evidence":"Phospho-specific immunoblots, HDAC6 activity and migration assays; WDR68 knockout cells with proteasome controls","pmids":["30317528","30496304"],"confidence":"Medium","gaps":["Direct vs. indirect GSK3β phosphorylation not fully isolated","Molecular role of WDR68 in maturation undefined"]},{"year":2020,"claim":"Revealed a genome-protection function: DYRK1B is recruited to DNA double-strand breaks and phosphorylates EHMT2 to enforce DSB-induced transcriptional silencing and efficient repair, a role distinct from its cell-cycle/metabolic functions.","evidence":"Kinome chemical screen, laser micro-irradiation with live imaging, kinase-dead/knockout, EHMT2 phosphorylation and transcription-rescue assays","pmids":["32611815"],"confidence":"High","gaps":["Recruitment mechanism to break sites not defined","Full DSB substrate set beyond EHMT2 unknown"]},{"year":2021,"claim":"Extended the DSB role to the nucleolus (rDNA transcription suppression and repair, ATM-uncoupled) and identified 4E-BP1/autophagy as a muscle-differentiation effector disrupted by the R102C disease allele.","evidence":"Targeted rDNA DSBs with micro-irradiation and rDNA copy-number assays; proteomics, zebrafish CRISPR knockout, autophagy-flux rescue","pmids":["33469661","34752933"],"confidence":"High","gaps":["Nucleolar substrate(s) for rDNA suppression not identified","Whether DSB and metabolic functions are mechanistically linked unknown"]},{"year":2022,"claim":"Defined major disease-driving outputs: kinase-independent mTORC2 activation drives hepatic lipogenesis and NASH (rescued by mTORC2 disruption), STAT3 binding amplifies cardiac/inflammatory signaling, and species-divergent C-lobe sequences explain DYRK1B's poor in vitro maturation.","evidence":"Liver AAV overexpression with genetic mTORC2 rescue; transgenic/KO TAC hearts with STAT3 Co-IP; bacterial cell-free autophosphorylation and thermal-stability assays","pmids":["34855620","35235343","35165364"],"confidence":"High","gaps":["How a kinase activates mTORC2 without catalysis unresolved","Direct binding interface with STAT3 not mapped"]},{"year":2023,"claim":"Identified FOXO1 (Ser329) phosphorylation controlling its localization as the basis for DYRK1B's role in CD4+ T-cell fate, balancing Treg versus Th1/Th17 differentiation.","evidence":"DYRK1B inhibitor treatment, FOXO1 phospho-specific assays, T-cell differentiation FACS and murine CHS model","pmids":["37120440"],"confidence":"Medium","gaps":["Site Ser329 vs later-reported Thr467/Ser468 reconciliation needed","Direct vs indirect phosphorylation not fully isolated"]},{"year":2024,"claim":"Expanded the cancer and metabolic roles: DYRK1B suppresses the CD24 'don't eat me' signal to evade macrophage phagocytosis in pancreatic cancer, and promotes WBP2 ubiquitin-dependent degradation to impair hepatic insulin signaling.","evidence":"Autochthonous/transplant PDAC models with genetic and pharmacological loss, phagocytosis assays; mouse overexpression/KO, proteomics, ubiquitylation and WBP2 rescue","pmids":["38834297","39296215"],"confidence":"High","gaps":["Mechanism linking DYRK1B activity to CD24 surface levels undefined","Whether WBP2 degradation requires direct phosphorylation unclear"]},{"year":2025,"claim":"Mature mechanistic synthesis: defined FOXO1 Thr467/Ser468 phosphorylation driving hepatic gluconeogenesis (with liver cKO protection), resolved CMGC-insert/proline-dependent maturation and disease variant R349W effects, solved the AZ191-bound crystal structure explaining selectivity, and linked DYRK1B/STAT3 to inflammatory resolution.","evidence":"In vivo/in vitro kinase assays with liver cKO; domain swaps and point mutants; X-ray crystallography; small-molecule inhibitor inflammation models","pmids":["40287828","41444824","41061777","39985685","41888523"],"confidence":"High","gaps":["How the diverse substrate repertoire is selected in different tissues remains unresolved","RFX7 negative-feedback role's physiological significance not established"]},{"year":null,"claim":"It remains unknown how a single kinase coordinates its opposing kinase-dependent (substrate phosphorylation) and kinase-independent (mTORC2 activation) outputs and selects among its many substrates across muscle, cancer, immune, and metabolic contexts.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified model for tissue-specific substrate selection","Kinase-independent scaffolding mechanism for mTORC2 undefined","Recruitment determinants to DSB/nucleolar sites unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[7,8,9,10,23,28,36]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[7,8,19,22,36]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,9,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[30,35]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,7,17]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10,21,25]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[29]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[28]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[7,16,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,9]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[28,29]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,12,24,31]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[30,36,40]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[6,8,23]}],"complexes":["mTORC2","MIRK–DCoHm–HNF1α complex"],"partners":["MKK3","RANBPM","STAT3","RFX7","CIRP","WDR68","CDC37","NKX3.1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y463","full_name":"Dual specificity tyrosine-phosphorylation-regulated kinase 1B","aliases":["Minibrain-related kinase","Mirk protein kinase"],"length_aa":629,"mass_kda":69.2,"function":"Dual-specificity kinase which possesses both serine/threonine and tyrosine kinase activities. Plays an essential role in ribosomal DNA (rDNA) double-strand break repair and rDNA copy number maintenance (PubMed:33469661). During DNA damage, mediates transcription silencing in part via phosphorylating and enforcing DSB accumulation of the histone methyltransferase EHMT2 (PubMed:32611815). Enhances the transcriptional activity of TCF1/HNF1A and FOXO1. Inhibits epithelial cell migration. Mediates colon carcinoma cell survival in mitogen-poor environments. Inhibits the SHH and WNT1 pathways, thereby enhancing adipogenesis. In addition, promotes expression of the gluconeogenic enzyme glucose-6-phosphatase catalytic subunit 1 (G6PC1)","subcellular_location":"Nucleus; Nucleus, nucleolus; Chromosome","url":"https://www.uniprot.org/uniprotkb/Q9Y463/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DYRK1B","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/DYRK1B","total_profiled":1310},"omim":[{"mim_id":"615812","title":"ABDOMINAL OBESITY-METABOLIC SYNDROME 3; AOMS3","url":"https://www.omim.org/entry/615812"},{"mim_id":"609836","title":"PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE 2; PCBD2","url":"https://www.omim.org/entry/609836"},{"mim_id":"606868","title":"HOMEODOMAIN-INTERACTING PROTEIN KINASE 2; HIPK2","url":"https://www.omim.org/entry/606868"},{"mim_id":"605552","title":"ABDOMINAL OBESITY-METABOLIC SYNDROME 1; AOMS1","url":"https://www.omim.org/entry/605552"},{"mim_id":"604556","title":"DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 1B; DYRK1B","url":"https://www.omim.org/entry/604556"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Mitotic chromosome","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":124.8},{"tissue":"testis","ntpm":79.9}],"url":"https://www.proteinatlas.org/search/DYRK1B"},"hgnc":{"alias_symbol":["MIRK"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y463","domains":[{"cath_id":"3.30.200.20","chopping":"93-190","consensus_level":"high","plddt":96.415,"start":93,"end":190},{"cath_id":"1.10.510.10","chopping":"194-433","consensus_level":"high","plddt":95.0347,"start":194,"end":433}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y463","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y463-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y463-F1-predicted_aligned_error_v6.png","plddt_mean":73.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DYRK1B","jax_strain_url":"https://www.jax.org/strain/search?query=DYRK1B"},"sequence":{"accession":"Q9Y463","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y463.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y463/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y463"}},"corpus_meta":[{"pmid":"35235343","id":"PMC_35235343","title":"DYRK1B-STAT3 Drives Cardiac Hypertrophy and Heart Failure by Impairing Mitochondrial Bioenergetics.","date":"2022","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/35235343","citation_count":157,"is_preprint":false},{"pmid":"20512148","id":"PMC_20512148","title":"DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS.","date":"2010","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20512148","citation_count":131,"is_preprint":false},{"pmid":"15010468","id":"PMC_15010468","title":"The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15010468","citation_count":119,"is_preprint":false},{"pmid":"24827035","id":"PMC_24827035","title":"A form of the metabolic syndrome associated with mutations in DYRK1B.","date":"2014","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24827035","citation_count":114,"is_preprint":false},{"pmid":"15075324","id":"PMC_15075324","title":"Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15075324","citation_count":107,"is_preprint":false},{"pmid":"10910078","id":"PMC_10910078","title":"Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10910078","citation_count":96,"is_preprint":false},{"pmid":"15851482","id":"PMC_15851482","title":"Mirk/Dyrk1B mediates survival during the differentiation of C2C12 myoblasts.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15851482","citation_count":84,"is_preprint":false},{"pmid":"19351855","id":"PMC_19351855","title":"Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19351855","citation_count":80,"is_preprint":false},{"pmid":"12902328","id":"PMC_12902328","title":"Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12902328","citation_count":79,"is_preprint":false},{"pmid":"22711815","id":"PMC_22711815","title":"Cold-inducible RNA-binding protein (Cirp) interacts with Dyrk1b/Mirk and promotes proliferation of immature male germ cells in mice.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22711815","citation_count":72,"is_preprint":false},{"pmid":"24134204","id":"PMC_24134204","title":"A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).","date":"2014","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/24134204","citation_count":69,"is_preprint":false},{"pmid":"9918863","id":"PMC_9918863","title":"Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9918863","citation_count":67,"is_preprint":false},{"pmid":"17583556","id":"PMC_17583556","title":"Mirk/Dyrk1B in cancer.","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17583556","citation_count":65,"is_preprint":false},{"pmid":"14500717","id":"PMC_14500717","title":"Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial cell migration and is negatively regulated by the Met adaptor Ran-binding protein M.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14500717","citation_count":63,"is_preprint":false},{"pmid":"27903983","id":"PMC_27903983","title":"DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27903983","citation_count":63,"is_preprint":false},{"pmid":"11980910","id":"PMC_11980910","title":"Mirk protein kinase is activated by MKK3 and functions as a transcriptional activator of HNF1alpha.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11980910","citation_count":62,"is_preprint":false},{"pmid":"15546868","id":"PMC_15546868","title":"Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15546868","citation_count":62,"is_preprint":false},{"pmid":"29193696","id":"PMC_29193696","title":"A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy.","date":"2017","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/29193696","citation_count":60,"is_preprint":false},{"pmid":"21878655","id":"PMC_21878655","title":"Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.","date":"2011","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21878655","citation_count":58,"is_preprint":false},{"pmid":"26784250","id":"PMC_26784250","title":"DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26784250","citation_count":56,"is_preprint":false},{"pmid":"16618736","id":"PMC_16618736","title":"The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16618736","citation_count":55,"is_preprint":false},{"pmid":"19633423","id":"PMC_19633423","title":"Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.","date":"2009","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19633423","citation_count":53,"is_preprint":false},{"pmid":"18818203","id":"PMC_18818203","title":"G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18818203","citation_count":53,"is_preprint":false},{"pmid":"16845176","id":"PMC_16845176","title":"Mirk/Dyrk1B: a multifunctional dual-specificity kinase involved in growth arrest, differentiation, and cell survival.","date":"2006","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/16845176","citation_count":52,"is_preprint":false},{"pmid":"19542220","id":"PMC_19542220","title":"Mirk regulates the exit of colon cancer cells from quiescence.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19542220","citation_count":49,"is_preprint":false},{"pmid":"17046823","id":"PMC_17046823","title":"Involvement of GSK-3beta and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17046823","citation_count":47,"is_preprint":false},{"pmid":"22159921","id":"PMC_22159921","title":"The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.","date":"2011","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22159921","citation_count":45,"is_preprint":false},{"pmid":"16707437","id":"PMC_16707437","title":"Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16707437","citation_count":42,"is_preprint":false},{"pmid":"17671193","id":"PMC_17671193","title":"The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17671193","citation_count":42,"is_preprint":false},{"pmid":"20042639","id":"PMC_20042639","title":"The kinase Mirk is a potential therapeutic target in osteosarcoma.","date":"2009","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20042639","citation_count":42,"is_preprint":false},{"pmid":"23311607","id":"PMC_23311607","title":"Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells.","date":"2013","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/23311607","citation_count":41,"is_preprint":false},{"pmid":"24239188","id":"PMC_24239188","title":"Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.","date":"2013","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24239188","citation_count":39,"is_preprint":false},{"pmid":"20857490","id":"PMC_20857490","title":"Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/RB2.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20857490","citation_count":38,"is_preprint":false},{"pmid":"23114871","id":"PMC_23114871","title":"Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23114871","citation_count":36,"is_preprint":false},{"pmid":"32611815","id":"PMC_32611815","title":"Screen identifies DYRK1B network as mediator of transcription repression on damaged chromatin.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32611815","citation_count":34,"is_preprint":false},{"pmid":"34855620","id":"PMC_34855620","title":"Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34855620","citation_count":33,"is_preprint":false},{"pmid":"21113238","id":"PMC_21113238","title":"Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells.","date":"2010","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21113238","citation_count":33,"is_preprint":false},{"pmid":"23528858","id":"PMC_23528858","title":"Mirk/dyrk1B Kinase in Ovarian Cancer.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23528858","citation_count":31,"is_preprint":false},{"pmid":"28743892","id":"PMC_28743892","title":"DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28743892","citation_count":30,"is_preprint":false},{"pmid":"26854247","id":"PMC_26854247","title":"Iron-induced oxidative stress activates AKT and ERK1/2 and decreases Dyrk1B and PRMT1 in neuroblastoma SH-SY5Y cells.","date":"2015","source":"Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)","url":"https://pubmed.ncbi.nlm.nih.gov/26854247","citation_count":30,"is_preprint":false},{"pmid":"34143631","id":"PMC_34143631","title":"Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34143631","citation_count":29,"is_preprint":false},{"pmid":"26346493","id":"PMC_26346493","title":"Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.","date":"2015","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/26346493","citation_count":28,"is_preprint":false},{"pmid":"12384504","id":"PMC_12384504","title":"The transcriptional activator Mirk/Dyrk1B is sequestered by p38alpha/beta MAP kinase.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12384504","citation_count":27,"is_preprint":false},{"pmid":"24590896","id":"PMC_24590896","title":"Mirk/dyrk1B kinase is upregulated following inhibition of mTOR.","date":"2014","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24590896","citation_count":26,"is_preprint":false},{"pmid":"12455049","id":"PMC_12455049","title":"Rapid turnover of cell-cycle regulators found in Mirk/dyrk1B transfectants.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12455049","citation_count":26,"is_preprint":false},{"pmid":"25738750","id":"PMC_25738750","title":"Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25738750","citation_count":23,"is_preprint":false},{"pmid":"24955215","id":"PMC_24955215","title":"The normal function of the cancer kinase Mirk/dyrk1B is to reduce reactive oxygen species.","date":"2014","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24955215","citation_count":22,"is_preprint":false},{"pmid":"33469661","id":"PMC_33469661","title":"A DYRK1B-dependent pathway suppresses rDNA transcription in response to DNA damage.","date":"2021","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/33469661","citation_count":21,"is_preprint":false},{"pmid":"25352950","id":"PMC_25352950","title":"Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells.","date":"2014","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25352950","citation_count":21,"is_preprint":false},{"pmid":"24312406","id":"PMC_24312406","title":"Functional Interactions between BM88/Cend1, Ran-binding protein M and Dyrk1B kinase affect cyclin D1 levels and cell cycle progression/exit in mouse neuroblastoma cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24312406","citation_count":21,"is_preprint":false},{"pmid":"31010428","id":"PMC_31010428","title":"Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition.","date":"2019","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/31010428","citation_count":21,"is_preprint":false},{"pmid":"20014342","id":"PMC_20014342","title":"The zebrafish dyrk1b gene is important for endoderm formation.","date":"2010","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/20014342","citation_count":20,"is_preprint":false},{"pmid":"25777618","id":"PMC_25777618","title":"The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase.","date":"2015","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25777618","citation_count":20,"is_preprint":false},{"pmid":"24281169","id":"PMC_24281169","title":"The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer.","date":"2010","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/24281169","citation_count":19,"is_preprint":false},{"pmid":"37301518","id":"PMC_37301518","title":"DYRK1B inhibition exerts senolytic effects on endothelial cells and rescues endothelial dysfunctions.","date":"2023","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/37301518","citation_count":17,"is_preprint":false},{"pmid":"29568347","id":"PMC_29568347","title":"Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29568347","citation_count":17,"is_preprint":false},{"pmid":"25061503","id":"PMC_25061503","title":"Mirk kinase inhibition targets ovarian cancer ascites.","date":"2014","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25061503","citation_count":16,"is_preprint":false},{"pmid":"24377315","id":"PMC_24377315","title":"Comparison of cancer cell survival triggered by microtubule damage after turning Dyrk1B kinase on and off.","date":"2014","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/24377315","citation_count":15,"is_preprint":false},{"pmid":"34830933","id":"PMC_34830933","title":"Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34830933","citation_count":14,"is_preprint":false},{"pmid":"30496304","id":"PMC_30496304","title":"DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30496304","citation_count":14,"is_preprint":false},{"pmid":"38834297","id":"PMC_38834297","title":"DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer.","date":"2024","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/38834297","citation_count":13,"is_preprint":false},{"pmid":"16257974","id":"PMC_16257974","title":"The survival kinase Mirk/dyrk1B is activated through Rac1-MKK3 signaling.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16257974","citation_count":13,"is_preprint":false},{"pmid":"26307683","id":"PMC_26307683","title":"Role of dual specificity tyrosine-phosphorylation-regulated kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from quiescence.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26307683","citation_count":12,"is_preprint":false},{"pmid":"34490236","id":"PMC_34490236","title":"CIRBP Knockdown Attenuates Tumourigenesis and Improves the Chemosensitivity of Pancreatic Cancer via the Downregulation of DYRK1B.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34490236","citation_count":12,"is_preprint":false},{"pmid":"39344427","id":"PMC_39344427","title":"Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39344427","citation_count":11,"is_preprint":false},{"pmid":"30317528","id":"PMC_30317528","title":"DYRK1B regulates Hedgehog-induced microtubule acetylation.","date":"2018","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/30317528","citation_count":11,"is_preprint":false},{"pmid":"35165364","id":"PMC_35165364","title":"Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35165364","citation_count":11,"is_preprint":false},{"pmid":"29751999","id":"PMC_29751999","title":"Up-regulation of Dyrk1b promote astrocyte activation following lipopolysaccharide-induced neuroinflammation.","date":"2018","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/29751999","citation_count":11,"is_preprint":false},{"pmid":"38040123","id":"PMC_38040123","title":"Targeting the survival kinase DYRK1B: A novel approach to overcome radiotherapy-related treatment resistance.","date":"2023","source":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38040123","citation_count":9,"is_preprint":false},{"pmid":"34193236","id":"PMC_34193236","title":"Two novel variants in DYRK1B causative of AOMS3: expanding the clinical spectrum.","date":"2021","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34193236","citation_count":9,"is_preprint":false},{"pmid":"25696812","id":"PMC_25696812","title":"miR-9 enhances the transactivation of nuclear factor of activated T cells by targeting KPNB1 and DYRK1B.","date":"2015","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25696812","citation_count":9,"is_preprint":false},{"pmid":"38675189","id":"PMC_38675189","title":"Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy.","date":"2024","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/38675189","citation_count":8,"is_preprint":false},{"pmid":"37120440","id":"PMC_37120440","title":"Inhibition of DYRK1B suppresses inflammation in allergic contact dermatitis model and Th1/Th17 immune response.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37120440","citation_count":8,"is_preprint":false},{"pmid":"34752933","id":"PMC_34752933","title":"Dyrk1b promotes autophagy during skeletal muscle differentiation by upregulating 4e-bp1.","date":"2021","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/34752933","citation_count":7,"is_preprint":false},{"pmid":"39863750","id":"PMC_39863750","title":"A safe haven for cancer cells: tumor plus stroma control by DYRK1B.","date":"2025","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39863750","citation_count":7,"is_preprint":false},{"pmid":"30673861","id":"PMC_30673861","title":"How to design potent and selective DYRK1B inhibitors? Molecular modeling study.","date":"2019","source":"Journal of molecular modeling","url":"https://pubmed.ncbi.nlm.nih.gov/30673861","citation_count":7,"is_preprint":false},{"pmid":"35219102","id":"PMC_35219102","title":"Harmine suppresses collagen production in hepatic stellate cells by inhibiting DYRK1B.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35219102","citation_count":7,"is_preprint":false},{"pmid":"40287828","id":"PMC_40287828","title":"DYRK1B phosphorylates FOXO1 to promote hepatic gluconeogenesis.","date":"2025","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/40287828","citation_count":5,"is_preprint":false},{"pmid":"36318489","id":"PMC_36318489","title":"Analysis of DYRK1B, PPARG, and CEBPB Expression Patterns in Adipose-Derived Stem Cells from Patients Carrying DYRK1B R102C and Healthy Individuals During Adipogenesis.","date":"2022","source":"Metabolic syndrome and related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/36318489","citation_count":5,"is_preprint":false},{"pmid":"36239428","id":"PMC_36239428","title":"Novel Efficient Multistage Lead Optimization Pipeline Experimentally Validated for DYRK1B Selective Inhibitors.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36239428","citation_count":5,"is_preprint":false},{"pmid":"39397076","id":"PMC_39397076","title":"Differential regulation of expression of the protein kinases DYRK1A and DYRK1B in cancer cells.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39397076","citation_count":4,"is_preprint":false},{"pmid":"21559261","id":"PMC_21559261","title":"The role of mirk kinase in sarcomas.","date":"2011","source":"Sarcoma","url":"https://pubmed.ncbi.nlm.nih.gov/21559261","citation_count":3,"is_preprint":false},{"pmid":"41061777","id":"PMC_41061777","title":"Structural perspective on the design of selective DYRK1B inhibitors.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41061777","citation_count":3,"is_preprint":false},{"pmid":"38294527","id":"PMC_38294527","title":"Mirk/Dyrk1B controls ventral spinal cord development via Shh pathway.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38294527","citation_count":2,"is_preprint":false},{"pmid":"26899006","id":"PMC_26899006","title":"[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].","date":"2016","source":"Zhonghua fu chan ke za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/26899006","citation_count":2,"is_preprint":false},{"pmid":"35504513","id":"PMC_35504513","title":"Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B.","date":"2022","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/35504513","citation_count":2,"is_preprint":false},{"pmid":"23913162","id":"PMC_23913162","title":"Construction of conditional lentivirus-mediated shRNA vector targeting the human Mirk gene and identification of RNAi efficiency in rhabdomyosarcoma RD cells.","date":"2013","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23913162","citation_count":2,"is_preprint":false},{"pmid":"39985685","id":"PMC_39985685","title":"Inhibition of DYRK1B BY C81 impedes inflammatory processes in leukocytes by reducing STAT3 activity.","date":"2025","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/39985685","citation_count":2,"is_preprint":false},{"pmid":"39296215","id":"PMC_39296215","title":"Hepatic Dyrk1b impairs systemic glucose homeostasis by modulating Wbp2 expression in a kinase activity-dependent manner.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39296215","citation_count":1,"is_preprint":false},{"pmid":"40281477","id":"PMC_40281477","title":"Dyrk1b as a potential biomarker for sarcopenia in older adults.","date":"2025","source":"BMC geriatrics","url":"https://pubmed.ncbi.nlm.nih.gov/40281477","citation_count":1,"is_preprint":false},{"pmid":"40002350","id":"PMC_40002350","title":"Myocardial DYRK1B Expression Is Increased in Patients with Impaired Cardiac Contractility and Sleep-Disordered Breathing.","date":"2025","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40002350","citation_count":1,"is_preprint":false},{"pmid":"37580898","id":"PMC_37580898","title":"DYRK1B haploinsufficiency in a Holstein cattle with epilepsy.","date":"2023","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37580898","citation_count":1,"is_preprint":false},{"pmid":"38867326","id":"PMC_38867326","title":"Functional characterization of two DYRK1B variants causative of AOMS3.","date":"2024","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/38867326","citation_count":1,"is_preprint":false},{"pmid":"40063071","id":"PMC_40063071","title":"Identification of DYRK1b as a novel regulator of small extracellular vesicle release using a high throughput nanoscale flow cytometry screening platform.","date":"2025","source":"Nanoscale","url":"https://pubmed.ncbi.nlm.nih.gov/40063071","citation_count":1,"is_preprint":false},{"pmid":"41444824","id":"PMC_41444824","title":"Critical role of the CMGC insert sequence for tyrosine autophosphorylation in the protein kinase DYRK1B.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41444824","citation_count":0,"is_preprint":false},{"pmid":"41888523","id":"PMC_41888523","title":"The protein kinase DYRK1B is a p53 target gene and functions as a negative feedback regulator of the transcription factor RFX7.","date":"2026","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41888523","citation_count":0,"is_preprint":false},{"pmid":"42072479","id":"PMC_42072479","title":"DYRK1B Inhibition by AZ191 Sensitizes High-Grade Serous Ovarian Cancer to Niraparib Through Promoting Apoptosis and Ferroptosis.","date":"2026","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/42072479","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.01.15.632643","title":"Temperature vaulting: A method for screening of slow- and tight-binding inhibitors that selectively target kinases in their non-native state","date":"2025-01-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.15.632643","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50246,"output_tokens":11846,"usd":0.164214,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":23016,"output_tokens":7346,"usd":0.149365,"stage2_stop_reason":"end_turn"},"total_usd":0.313579,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"DYRK1B (MIRK) is a nuclear-localized serine/threonine kinase predominantly expressed in muscle and testis; a GFP fusion protein localizes mainly to the nucleus of transfected COS-7 cells, consistent with a bipartite nuclear localization motif in its sequence.\",\n      \"method\": \"GFP fusion protein transfection and fluorescence microscopy; sequence analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization experiment in cells with functional implication (nuclear kinase), single lab, one method\",\n      \"pmids\": [\"9918863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"DYRK1B (MIRK) is a downstream substrate of the MAPK pathway; activated ERKs down-regulate MIRK protein levels in vivo, and blocking MEK with PD98059 increases MIRK levels ~20-fold in colon carcinoma cells. Kinase-active MIRK (but not kinase-dead mutant) enables colon carcinoma cells to survive in serum-free medium.\",\n      \"method\": \"MEK inhibitor treatment, stable overexpression of wild-type vs. kinase-dead MIRK, serum-free growth assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase-dead controls used, multiple cell lines, single lab\",\n      \"pmids\": [\"10910078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"DYRK1B (MIRK) functions as a transcriptional co-activator of HNF1α by binding DCoHm (a dimerization cofactor of HNF1α), forming a MIRK–DCoHm–HNF1α complex; MIRK directly phosphorylates HNF1α at Ser249 within its CBP-binding domain. MKK3, an upstream stress-activated kinase, co-immunoprecipitates with MIRK and enhances its kinase activity and HNF1α transactivation.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, in vitro kinase assay, reporter assays with kinase-dead mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal binding methods, in vitro kinase assay, kinase-dead controls, functional reporter assays\",\n      \"pmids\": [\"11980910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"p38α and p38β (but not γ or δ) isoforms sequester DYRK1B (MIRK) in nuclear subnuclear complexes (~500–700 kDa) in a kinase-independent manner, preventing MIRK association with MKK3 and inhibiting its function as a transcriptional activator of HNF1α.\",\n      \"method\": \"Co-immunoprecipitation, size-exclusion FPLC fractionation, reporter assays, dominant-negative p38 constructs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, FPLC fractionation, functional reporter assays, isoform specificity tested, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"12384504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"DYRK1B (MIRK) is induced by Rho-family GTPases (RhoA, Cdc42, and to a lesser extent Rac1) during skeletal muscle differentiation, and is required for myoblast fusion and induction of differentiation markers (myogenin, troponin T, myosin heavy chain); depletion by siRNA blocks these events.\",\n      \"method\": \"Promoter-reporter assays, transient expression of constitutively active GTPases, siRNA knockdown with differentiation marker readouts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional loss-of-function (siRNA), gain-of-function, multiple differentiation markers, multiple cell lines, single lab with orthogonal methods\",\n      \"pmids\": [\"12902328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"DYRK1B (MIRK) was identified as a binding partner of the Met adaptor protein RanBPM by yeast two-hybrid, confirmed by GST pulldown, Co-IP, and in vivo cross-linking; RanBPM inhibits MIRK kinase activity. Induction of MIRK inhibits cell migration and invasion, an effect attenuated by HGF or overexpressed RanBPM.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown, Co-IP, in vivo cross-linking, stable inducible MIRK cell line, wounding and Transwell migration assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal binding methods, functional migration assays, kinase activity measurement, single lab\",\n      \"pmids\": [\"14500717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Stable overexpression of DYRK1B (MIRK) enhances proteasome-dependent turnover of p27Kip1, cyclin D1, and p21Cip1 at the protein level without affecting p27 mRNA or promoter activity, indicating post-transcriptional regulation.\",\n      \"method\": \"Stable transfectants (wild-type vs. kinase-dead), proteasome inhibitor experiments, mRNA and promoter assays\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase-dead controls, proteasome inhibitor validation, single lab\",\n      \"pmids\": [\"12455049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"DYRK1B (MIRK) directly phosphorylates p27Kip1 at Ser10 in G0, stabilizing p27 and maintaining G0 arrest; phosphomimetic p27-S10D is more stable than wild-type, and non-phosphorylatable p27-S10A is less stable. MIRK co-localizes with nuclear p27 in G0 and does not induce p27 nuclear export. Depletion of MIRK by RNAi decreases p27 phosphorylation at Ser10 and increases G0→G1 entry.\",\n      \"method\": \"In vitro kinase assay, phosphomimetic/non-phosphorylatable mutants, RNAi knockdown, PCNA and p27 protein/stability assays, co-localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay, mutant analysis, RNAi loss-of-function, replicated in multiple cell types\",\n      \"pmids\": [\"15010468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"DYRK1B (MIRK) binds cyclin D1 and phosphorylates it at Thr288 (in vivo and in vitro), promoting cyclin D1 destabilization; cyclin D1-T288A is more stable than wild-type. MIRK and GSK3β phosphorylate cyclin D1 additively at distinct sites. RNAi depletion of MIRK increases cyclin D1 protein without affecting mRNA.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, stable inducible MIRK transfectants, cyclin D1-T288A mutant, RNAi knockdown, GSK3β inhibitor LiCl\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay, binding demonstrated by Co-IP, phospho-site mutagenesis, RNAi, kinase inhibitor controls\",\n      \"pmids\": [\"15075324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"DYRK1B (MIRK) phosphorylates class II HDACs (HDAC5, MITR) at a conserved site within their nuclear localization region, reducing their nuclear accumulation in a dose- and kinase-dependent manner, thereby enabling MEF2C to activate the myogenin promoter during muscle differentiation. MIRK does not directly phosphorylate MEF2; the effect is indirect via HDAC phosphorylation.\",\n      \"method\": \"Co-expression studies, kinase-dead mutants, phosphomimetic MITR construct, reporter assays, subcellular localization of GFP-HDAC fusions, siRNA knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — kinase-dead controls, phosphomimetic mutants, localization experiments, functional reporter assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15546868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"DYRK1B (MIRK) phosphorylates p21Cip1 at Ser153 within its nuclear localization domain, causing a fraction of nuclear p21 to relocalize to the cytoplasm; cytoplasmic p21 blocks caspase 3 activation and promotes myoblast survival. Phosphomimetic p21-S153D localizes pan-cellularly and is more effective than wild-type at blocking caspase 3; non-phosphorylatable p21-S153A remains nuclear and has no survival effect.\",\n      \"method\": \"Overexpression and RNAi, GFP-p21 localization (fluorescence microscopy), phosphomimetic/non-phosphorylatable mutants, caspase 3 activation assays, colony-forming assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — phosphosite mutagenesis, localization experiments, functional caspase/survival assays, kinase-dead controls, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15851482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"DYRK1B (MIRK) is activated by signaling from Rac1 to MKK3; constitutively active Rac1QL activates MIRK through MKK3, which phosphorylates MIRK. Dominant-negative Rac1, dominant-negative MKK3, and MKK3 siRNA inhibit MIRK kinase activity. Endogenous Rac1 activates MIRK following E-cadherin ligation in confluent MDCK cells.\",\n      \"method\": \"Kinase activity assays, dominant-negative constructs, RNAi knockdown of MKK3, E-cadherin/Fc chimera engagement, Rac1 inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct kinase activity measurement, multiple genetic and pharmacological perturbations, endogenous signaling context confirmed, single lab\",\n      \"pmids\": [\"16257974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"DYRK1B (MIRK) is a novel downstream effector of oncogenic K-RAS in pancreatic cancer; K-RAS activates MIRK through Rac1→MKK3 signaling. Knockdown of K-RAS by three independent RNAi sequences, or of Rac1 by two independent RNAi sequences, or pharmacological Rac1 inhibition, or dominant-negative K-rasS17N all blocked MIRK activation.\",\n      \"method\": \"Reporter assays, RNAi knockdown (K-RAS, Rac1), dominant-negative K-ras, Rac1 inhibitor, kinase activity assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple independent RNAi sequences, pharmacological inhibitors, dominant-negative controls, consistent results across methods\",\n      \"pmids\": [\"17671193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BCL2 and BCL-xL stabilize p27 in G0 via MIRK-mediated phosphorylation of p27 at Ser10; this G0 function requires BAX and BAK, as the effect is lost in bax−/−bak−/− cells. Re-expression of BAX in double-knockout cells restores Ser10-p27 phosphorylation, demonstrating that BAX/BAK modulate MIRK-dependent p27 stabilization.\",\n      \"method\": \"Genetic knockout cells (bax−/−bak−/−), BAX re-expression, phospho-specific p27 Ser10 immunoblotting, cell cycle analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in knockout cells, phospho-specific readout, single lab\",\n      \"pmids\": [\"18818203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DYRK1B (MIRK) maintains viability of quiescent pancreatic cancer cells by increasing transcription of antioxidant genes (ferroxidase, SOD2, SOD3), thereby reducing intracellular ROS levels. Depletion of MIRK via inducible shRNA increases ROS, decreases colony-forming ability, and reduces viability; ectopic expression of SOD2 and ferroxidase rescues ROS levels in MIRK-depleted cells.\",\n      \"method\": \"Inducible shRNA knockdown, ROS measurement, antioxidant gene expression analysis, ectopic expression rescue, colony-forming assays, dye exclusion viability\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible knockdown with rescue experiment (ectopic antioxidant genes), multiple cell lines, ROS mechanistic link established\",\n      \"pmids\": [\"19351855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mutant RAS activates DYRK1B as part of a KRAS–DYRK1B network that mediates cell-autonomous negative regulation (antagonism) of autocrine Hedgehog (HH) signaling, interfering with Gli2 function and Gli3 processing, while simultaneously redirecting HH signaling toward a paracrine mode in pancreatic cancer.\",\n      \"method\": \"Genetic and cell biological studies in mutant RAS-expressing cells; RAS effector pathway analysis; Gli2/Gli3 processing assays\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — established pathway cross-talk via functional assays, single lab, mechanism partially defined\",\n      \"pmids\": [\"20512148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"DYRK1B (MIRK) regulates colon cancer cell exit from quiescence by destabilizing cyclin D1 and cyclin D3, reducing CDK4/cyclin D activity and p130/Rb2 phosphorylation, thereby maintaining the quiescent state. Depletion of MIRK increases cyclin D1/D3 protein via slower turnover and allows cells to escape G0. Cyclin D1-T288A (Mirk phosphorylation site mutant), but not wild-type cyclin D1, shortens 5-FU-induced G1, confirming site-specific mechanism.\",\n      \"method\": \"RNAi knockdown, cyclin D1-T288A mutant expression, CDK4 activity assays, p130 phosphorylation, Hoechst/Pyronin Y G0 staining\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — phospho-site mutant rescue, multiple mechanistic readouts, single lab with orthogonal methods\",\n      \"pmids\": [\"19542220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Cold-inducible RNA-binding protein CIRP directly binds DYRK1B/MIRK and inhibits its interaction with p27, resulting in decreased phosphorylation and destabilization of p27. CIRP does not affect DYRK1B binding to cyclin D1 but inhibits DYRK1B-mediated phosphorylation of cyclin D1, leading to cyclin D1 stabilization. CIRP and DYRK1B co-localize in the nucleus of undifferentiated spermatogonia.\",\n      \"method\": \"Co-immunoprecipitation (direct CIRP–DYRK1B binding), siRNA knockdown, protein stability assays, G0 fraction analysis, immunofluorescence co-localization in spermatogonia\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding confirmed by Co-IP, knockdown with consistent phenotype in vitro and in vivo (knockout mice), substrate-specific effects dissected\",\n      \"pmids\": [\"22711815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DYRK1B inhibits SHH and Wnt signaling pathways and enhances adipogenesis; the disease-associated R102C allele shows gain-of-function activity, potentiating these effects. DYRK1B also promotes expression of glucose-6-phosphatase (a key gluconeogenic enzyme).\",\n      \"method\": \"Functional characterization in patient-derived cell lines and model systems; pathway reporter assays; gene expression analysis; R102C gain-of-function mutant characterization\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional pathway assays with mutant characterization, single study with multiple pathway readouts\",\n      \"pmids\": [\"24827035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Using the selective DYRK1B inhibitor AZ191, it was demonstrated that DYRK1B phosphorylates cyclin D1 at Thr286 (not Thr288 as previously reported) in vitro and in cells, and this is independent of GSK3β. In PANC-1 and HEK293 cells, DYRK1B drives Thr286 phosphorylation and proteasome-dependent cyclin D1 turnover; AZ191 or DYRK1B RNAi abolishes this, while GSK3β inhibitors or GSK3β RNAi do not. DYRK1B also promotes p21CIP1 and p27KIP1 expression.\",\n      \"method\": \"In vitro kinase assay, phospho-specific immunoblot, mass spectrometry, selective small-molecule inhibitor (AZ191), DYRK1B RNAi, GSK3β RNAi and inhibitors\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay + MS phosphosite identification + selective inhibitor + RNAi, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"24134204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DYRK1B (MIRK) is upregulated several-fold by mTOR inhibitors (RAD001, WYE354, rapamycin) via CREB-mediated transcription; CREB binds two sites in the MIRK promoter and one site in exon 4. Depletion of CREB reduces MIRK expression; depletion of mTOR increases it. Activated Akt–ER construct blocks the mTOR-inhibitor-induced increase in MIRK mRNA.\",\n      \"method\": \"mTOR inhibitor treatment, CREB ChIP/reporter assays, siRNA knockdown of CREB and mTOR, inducible Akt-ER construct\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding, siRNA knockdown, pathway manipulation, single lab\",\n      \"pmids\": [\"24590896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DYRK1B (MIRK) in differentiated skeletal muscle (fast-twitch fibers) and cycling myoblasts reduces ROS by maintaining expression of antioxidant genes; pharmacological MIRK kinase inhibition or depletion increases ROS in both C2C12 myoblasts and differentiated myotubes. MIRK protein translocates from nucleus (cycling myoblasts) to cytoplasm (differentiating myoblasts and mature fast-twitch fibers).\",\n      \"method\": \"MIRK kinase inhibitor treatment, inducible shRNA, ROS measurement, immunofluorescence and cell fractionation for localization, antioxidant gene expression\",\n      \"journal\": \"Genes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by fractionation and imaging with functional consequence, inhibitor and knockdown convergence, single lab\",\n      \"pmids\": [\"24955215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DYRK1B is a substrate of ERK2: ERK2 phosphorylates DYRK1B at Ser421 in vitro; selective ERK1/2 pathway activation increases p-S421 in cells. DYRK1B also trans-autophosphorylates at S421 in vitro and in cells. A catalytically inactive DYRK1B(D239A) mutant has very low p-S421 in cells, increased by KRAS(G12V). S421 phosphorylation contributes to DYRK1B kinase activity. DYRK1B is activated by cis-autophosphorylation on Y273 during translation.\",\n      \"method\": \"In vitro kinase assay with recombinant ERK2, phospho-specific immunoblot, selective MEK inhibitors, pathway-selective activation constructs, kinase-dead DYRK1B mutants, KRAS(G12V) expression\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, multiple mutants, selective inhibitors, consistent in vitro and in-cell results\",\n      \"pmids\": [\"26346493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DYRK1B interacts with the tumor suppressor NKX3.1 via the DYRK1B kinase domain and phosphorylates NKX3.1 at Ser185 in vitro, promoting NKX3.1 degradation; this residue is critical for NKX3.1 steady-state turnover. Small-molecule DYRK1B inhibitors prolonged NKX3.1 half-life.\",\n      \"method\": \"siRNA kinase screen, Co-IP (kinase domain interaction), in vitro kinase assay, phospho-specific site (S185) mutagenesis, protein stability/half-life assays, small-molecule inhibitors\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro kinase assay, binding domain defined, phosphosite mutagenesis, inhibitor validation, multiple methods\",\n      \"pmids\": [\"25777618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DYRK1B mediates Hedgehog (Hh)-induced mTOR/AKT activation: Hh signaling induces DYRK1B protein expression in fibroblasts, which then activates the mTOR/AKT kinase signaling arm. DYRK1B exerts negative feedback on canonical SMO-mediated Hh/GLI signaling while providing positive feed-forward regulation by promoting AKT-mediated GLI stability.\",\n      \"method\": \"Genetic and pharmacological inhibition of DYRK1B, Hh pathway stimulation, AKT/mTOR phosphorylation readouts, GLI1 expression assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and chemical inhibition with pathway readouts, single lab, mechanism partially defined\",\n      \"pmids\": [\"27903983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DYRK1B missense mutations (H90P and R102C) affecting the DYRK homology (DH) box do not alter the specific catalytic activity of mature DYRK1B but cause accumulation of the mutant protein in detergent-insoluble cytoplasmic aggregates in an underphosphorylated (on tyrosine) form. Mutant DYRK1B shows enhanced binding to co-chaperone CDC37 and greater sensitivity to the HSP90 inhibitor ganetespib, indicating impaired chaperone-dependent maturation.\",\n      \"method\": \"Cellular kinase activity assays, detergent fractionation, phospho-tyrosine immunoblotting, HSP90 inhibitor sensitivity, Co-IP with CDC37\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical assays, single lab, mechanism of misfolding defined\",\n      \"pmids\": [\"28743892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DYRK1B mediates Hedgehog-induced microtubule (MT) acetylation by inhibiting GSK3β through phosphorylation of GSK3β Serine 9, which suppresses HDAC6 activity (a major tubulin deacetylase), resulting in increased acetylated MTs. This DYRK1B-dependent MT acetylation facilitates mitochondrial transport, mesenchymal cell polarization, and directed cell migration.\",\n      \"method\": \"Hh pathway stimulation, DYRK1B knockdown/inhibition, GSK3β S9 phospho-specific immunoblot, HDAC6 activity assay, MT acetylation assays, mitochondrial transport and migration assays\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phospho-specific substrate readout, functional downstream consequence, single lab\",\n      \"pmids\": [\"30317528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"WDR68 (DCAF7) is required for normal protein levels of DYRK1B (and DYRK1A); WDR68 knockout in C2C12 and HeLa cells reduces DYRK1B protein levels without affecting mRNA, and proteasome inhibition does not restore DYRK1B, suggesting WDR68 is required for proper kinase stabilization/maturation rather than preventing proteasomal degradation.\",\n      \"method\": \"Engineered knockout cell lines, Western blotting, RT-PCR, proteasome inhibitor treatment, WDR68 overexpression\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout, multiple negative controls, single lab\",\n      \"pmids\": [\"30496304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"DYRK1B is recruited to laser-microirradiated DNA double-strand break (DSB) sites, and its kinase activity is required for DSB-induced transcriptional silencing on active chromatin and for efficient DNA repair. DYRK1B phosphorylates the histone methyltransferase EHMT2, enforcing its DSB accumulation, establishing a DYRK1B–EHMT2 axis. Genetic inactivation of DYRK1B or its kinase activity attenuates DSB-induced gene silencing and impairs DNA repair.\",\n      \"method\": \"Kinome-wide chemical screen, laser micro-irradiation, live-cell imaging of DYRK1B recruitment, genetic inactivation (knockout/kinase-dead), global transcription shutdown rescue, EHMT2 phosphorylation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live imaging of recruitment, kinase-dead mutant, genetic knockout, substrate phosphorylation, rescue experiments, multiple orthogonal methods\",\n      \"pmids\": [\"32611815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DYRK1B is required for full suppression of rDNA (ribosomal DNA) transcription following DSBs, exhibiting robust nucleolar accumulation after laser micro-irradiation. DYRK1B inactivation leads to sustained nucleolar transcription after DSBs, impaired rDNA DSB repair, and reduced rDNA copy number maintenance. This nucleolar DSB response can be uncoupled from ATM-mediated DSB signaling.\",\n      \"method\": \"Targeted rDNA DSBs, laser micro-irradiation, chemical inhibition and genetic inactivation of DYRK1B, rRNA synthesis assays, rDNA copy number analysis, cell sensitivity assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — targeted rDNA DSBs, chemical and genetic inhibition, multiple functional readouts, single lab with orthogonal methods\",\n      \"pmids\": [\"33469661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DYRK1B promotes hepatic lipogenesis by activating mTORC2 in a kinase-independent fashion. Dyrk1b overexpression in mouse liver enhanced de novo lipogenesis, fatty acid uptake, triacylglycerol secretion, and caused NASH; the Dyrk1b-induced NASH was fully rescued when mTORC2 was genetically disrupted. The resulting elevated diacylglycerol activated PKCε and led to IRKT1150 phosphorylation, impairing hepatic insulin signaling.\",\n      \"method\": \"Liver-specific AAV-mediated overexpression, genetic mTORC2 disruption (rescue experiment), Dyrk1b knockdown, lipogenesis assays, PKCε and IR phosphorylation assays, in vivo mouse models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue (mTORC2 KO fully rescues), kinase-independent mechanism established, multiple in vivo and in vitro readouts\",\n      \"pmids\": [\"34855620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DYRK1B directly binds STAT3 and increases its phosphorylation and nuclear accumulation, contributing to downregulation of PGC-1α and impaired mitochondrial bioenergetics in cardiac hypertrophy and heart failure. Cardiac-specific DYRK1B overexpression causes cardiac dysfunction; DYRK1B knockout mitigates TAC-induced cardiac hypertrophy and heart failure.\",\n      \"method\": \"Transgenic and knockout mice (TAC model), Co-IP (DYRK1B–STAT3 binding), STAT3 phosphorylation and nuclear accumulation assays, PGC-1α expression, mitochondrial functional analysis, specific inhibitors\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic and KO models, direct binding by Co-IP, phosphorylation and localization readouts, inhibitor validation\",\n      \"pmids\": [\"35235343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DYRK1B maturation requires the CMGC insert and adjacent sequences; human DYRK1B autophosphorylation is severely compromised in bacterial cell-free systems (unlike DYRK1A or zebrafish/Xenopus DYRK1B orthologs), and the differential folding is largely due to divergent C-terminal lobe sequences. DYRK1B's mature kinase domain has lower thermal stability than DYRK1A.\",\n      \"method\": \"Bacterial expression systems (cell-free), autophosphorylation assays, thermal stability assays, domain comparison across species, heat challenge in vitro and in cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution and biochemical assays, single lab, ortholog comparison but limited to single study\",\n      \"pmids\": [\"35165364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DYRK1B phosphorylates FOXO1 at Ser329 to regulate its cytoplasmic/nuclear localization; DYRK1B inhibition enhances nuclear FOXO1 retention (by blocking Ser329 phosphorylation), promoting Treg differentiation and suppressing Th1/Th17 differentiation in CD4+ T cells.\",\n      \"method\": \"DYRK1B inhibitor treatment, FOXO1 phospho-specific assays (Ser329), T cell differentiation assays (FACS), Treg/Th1/Th17 marker analysis, murine CHS model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phospho-specific substrate site identified, in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"37120440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DYRK1B downregulates the phagocytosis checkpoint 'don't eat me' signal CD24 on pancreatic cancer cells; genetic ablation or pharmacological inhibition of DYRK1B strongly attracts tumoricidal macrophages and enhances tumor cell phagocytosis. Tumor cells lacking DYRK1B barely expand in vivo despite growing rapidly in culture.\",\n      \"method\": \"Transplantation and autochthonous mouse PDAC models, genetic Dyrk1b loss, pharmacological inhibition, co-culture experiments, CD24 surface expression analysis, phagocytosis assays, bulk mRNA sequencing and proteomics (secretomics)\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic and pharmacological models, direct mechanistic link to CD24 and phagocytosis, multiple orthogonal approaches\",\n      \"pmids\": [\"38834297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DYRK1B is a novel substrate of and negative feedback regulator on the transcription factor RFX7: DYRK1B is induced by cytostatic drugs (Actinomycin D, Doxorubicin) via p53-dependent activation of RFX7; DYRK1B physically interacts with RFX7 and counteracts its p53-mediated activation in a catalytic-activity-dependent manner, establishing a negative feedback loop.\",\n      \"method\": \"Drug treatment in multiple cancer cell lines, p53-dependent induction assays, Co-IP (DYRK1B–RFX7 interaction), kinase-dead DYRK1B mutants, DYRK1 small-molecule inhibitors\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP binding, kinase-dead controls, inhibitor validation, single lab\",\n      \"pmids\": [\"41888523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DYRK1B promotes hepatic gluconeogenesis and glucose intolerance by interacting with and phosphorylating FOXO1 primarily at Thr467/Ser468, which is essential for FOXO1 nuclear localization; additionally, DYRK1B inhibits AKT-mediated FOXO1 phosphorylation at Thr24 and Ser256, enhancing FOXO1 nuclear retention and gluconeogenic gene expression. Liver-specific Dyrk1b conditional knockout mice are protected from diet-induced hyperglycemia.\",\n      \"method\": \"In vivo/in vitro kinase assays, liver-specific Dyrk1b cKO mice, Co-IP (DYRK1B–FOXO1), phospho-specific immunoblotting at FOXO1 sites, gluconeogenesis gene expression assays, AZ191 pharmacological inhibitor\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro and in vivo kinase evidence, conditional KO rescue, phospho-site–specific analysis, multiple orthogonal methods\",\n      \"pmids\": [\"40287828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The CMGC insert sequence and two adjacent proline residues (P332/P333 in DYRK1B) are critical for DYRK1B tyrosine autophosphorylation and maturation; mutation of either proline impairs autophosphorylation and nuclear localization. Substitution of the DYRK1B CMGC insert with that of DYRK1A rescues the maturation defect. The pathogenic R349W mutation associated with monogenic obesity/type 2 diabetes also disrupts autophosphorylation.\",\n      \"method\": \"Domain swaps, point mutations, autophosphorylation assays, nuclear localization studies, X-ray crystallography structural context\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — domain swap rescue experiments, multiple point mutants, functional and localization readouts, disease-variant correlation\",\n      \"pmids\": [\"41444824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DYRK1B crystal structure was solved in complex with the inhibitor AZ191, revealing features in the hinge-binding region and differential accessibility of the catalytic lysine compared to DYRK1A that are pivotal for kinase selectivity.\",\n      \"method\": \"X-ray crystallography, quantum-mechanical and molecular-dynamics analyses, enzyme inhibition assays, cellular target engagement\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure determination with functional validation, multiple biophysical and biochemical methods\",\n      \"pmids\": [\"41061777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DYRK1B inhibition reduces STAT3 phosphorylation in leukocytes, leading to decreased integrin activation, reduced leukocyte adhesion/migration, suppression of pro-inflammatory cytokines and eicosanoids, induction of apoptosis in neutrophils, and increased efferocytosis; this DYRK1B/STAT3 axis is identified as a regulator of inflammatory resolution.\",\n      \"method\": \"Small-molecule DYRK1B inhibitor (C81), STAT3 phosphorylation assays, leukocyte adhesion/migration assays, cytokine measurements, murine psoriasis and choroidal neovascularization models\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition, phospho-specific substrate readout, in vivo models, single lab\",\n      \"pmids\": [\"39985685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DYRK1B promotes proteasomal degradation of WBP2 through enhanced WBP2 ubiquitylation (kinase-activity-dependent), thereby impairing hepatic insulin signaling; restoration of WBP2 partially rescues DYRK1B overexpression-induced glucose intolerance in vivo.\",\n      \"method\": \"Dyrk1b overexpression/knockout in mice, quantitative proteomics, ubiquitylation assays, WBP2 rescue experiments, kinase-dead mutant controls\",\n      \"journal\": \"Heliyon\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomics discovery, ubiquitylation assay, in vivo rescue, kinase-dead controls, single lab\",\n      \"pmids\": [\"39296215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DYRK1B upregulates 4E-BP1 (a translational inhibitor) in C2C12 myofibers as a post-transcriptional target; CRISPR/Cas9 knockout of Dyrk1b in zebrafish also identifies 4E-BP1 as a downstream target in vivo. 4E-BP1 enhances autophagy and mediates Dyrk1b's effects on skeletal muscle differentiation. The disease-associated Dyrk1bR102C mutation impairs muscle differentiation via excessive 4E-BP1/autophagy activation, rescued by reduction of autophagic flux.\",\n      \"method\": \"Untargeted proteomics (C2C12), CRISPR/Cas9 zebrafish knockout, siRNA knockdown and overexpression in C2C12, autophagy flux assays, rescue experiments\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomics discovery confirmed in vivo (zebrafish KO), functional rescue, multiple genetic approaches, single lab\",\n      \"pmids\": [\"34752933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DYRK1B kinase inhibition by AZ191 reduces total small extracellular vesicle (EV) number and alters intracellular distribution of the EV marker CD63, suggesting DYRK1B plays a role in EV trafficking. DYRK1B knockdown confirms the EV reduction effect.\",\n      \"method\": \"High-throughput nanoscale flow cytometry, kinase inhibitor screen (AZ191), siRNA knockdown, CD63 intracellular distribution imaging\",\n      \"journal\": \"Nanoscale\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pharmacological inhibitor plus knockdown, mechanistic pathway not fully resolved\",\n      \"pmids\": [\"40063071\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DYRK1B (MIRK) is a nuclear/cytoplasmic serine/threonine kinase that is activated by cis-autophosphorylation on Y273 during translation (requiring the CMGC insert and adjacent prolines), further regulated by MKK3-mediated phosphorylation downstream of Rac1 and K-RAS, and by ERK2-mediated phosphorylation at S421; it maintains cellular quiescence by directly phosphorylating and stabilizing p27Kip1 (Ser10), destabilizing cyclin D1 (Thr286) and cyclin D3, phosphorylating and redistributing p21Cip1 (Ser153) to the cytoplasm for anti-apoptotic function, and phosphorylating class II HDACs to relieve MEF2-mediated transcription during myogenesis; it promotes cell survival by upregulating antioxidant genes (SOD2, SOD3, ferroxidase) to reduce ROS, binds STAT3 to increase its phosphorylation and nuclear accumulation, phosphorylates FOXO1 (Thr467/Ser468) to regulate gluconeogenesis and T-cell differentiation, phosphorylates NKX3.1 (Ser185) to promote its degradation, activates mTORC2 in a kinase-independent manner to drive hepatic lipogenesis, interacts with and negatively regulates the transcription factor RFX7 downstream of p53, mediates DSB-induced transcriptional silencing via phosphorylation of EHMT2, and controls rDNA transcription suppression and repair after nucleolar DSBs.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"DYRK1B (MIRK) is a dual-specificity nuclear/cytoplasmic serine/threonine kinase that enforces cellular quiescence and survival across muscle, cancer, and metabolic tissues [#0, #7, #14]. Its activation requires cis-autophosphorylation on Y273 during translation, a maturation step uniquely dependent on the CMGC insert and adjacent prolines P332/P333 and on the co-chaperone factors WDR68/DCAF7 and HSP90/CDC37 [#22, #37, #25, #27]; activity is further tuned by an upstream Rac1\\u2192MKK3 module activated downstream of oncogenic K-RAS and by ERK2-mediated phosphorylation at S421 [#11, #12, #22]. A central function is post-transcriptional control of the cell-cycle machinery: DYRK1B phosphorylates p27Kip1 at Ser10 to stabilize it and maintain G0 arrest, phosphorylates cyclin D1 (Thr286) and cyclin D3 to drive their proteasomal turnover, and phosphorylates p21Cip1 at Ser153 to redistribute it to the cytoplasm where it blocks caspase-3 activation and promotes survival [#7, #16, #19, #10]. In skeletal muscle it drives differentiation by phosphorylating class II HDACs to relieve MEF2-dependent transcription, and supports quiescent-cell viability by upregulating antioxidant genes (SOD2, SOD3, ferroxidase) to suppress ROS [#9, #4, #14, #21]. DYRK1B also phosphorylates additional substrates to control their stability or localization\\u2014NKX3.1 (Ser185, degradation), FOXO1 (Thr467/Ser468, nuclear retention and gluconeogenesis), and EHMT2 during the DNA damage response\\u2014and is recruited to DNA double-strand breaks and nucleoli to enforce transcriptional silencing and rDNA repair [#23, #36, #28, #29]. In metabolic disease it promotes hepatic lipogenesis through kinase-independent activation of mTORC2 and gluconeogenesis via FOXO1, with liver-specific knockout protecting against hyperglycemia [#30, #36], and it binds STAT3 to amplify its phosphorylation and nuclear accumulation in cardiac hypertrophy and inflammation [#31, #39]. Gain-of-function coding variants (R102C, R349W) cause a monogenic metabolic syndrome of central obesity and type 2 diabetes, acting through impaired maturation and altered downstream signaling [#18, #37].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established DYRK1B's basic identity and subcellular address: it is a nuclear serine/threonine kinase enriched in muscle and testis, defining the tissues where its biology would later be dissected.\",\n      \"evidence\": \"GFP-fusion localization in COS-7 cells and sequence analysis\",\n      \"pmids\": [\"9918863\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No substrate or pathway identified\", \"Single localization method in one cell type\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Placed DYRK1B downstream of MAPK signaling and assigned it a survival function, showing kinase-active MIRK lets carcinoma cells survive serum withdrawal while ERK activity suppresses MIRK protein.\",\n      \"evidence\": \"MEK inhibitor treatment and wild-type vs. kinase-dead overexpression with serum-free survival assays\",\n      \"pmids\": [\"10910078\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of ERK-dependent downregulation not defined\", \"Survival effector substrates unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolved the proximal regulatory inputs to MIRK by identifying MKK3 as an activating upstream kinase and p38\\u03b1/\\u03b2 as kinase-independent sequestering inhibitors, and defined HNF1\\u03b1 (Ser249) as a transcriptional substrate.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP/FPLC fractionation, in vitro kinase and reporter assays\",\n      \"pmids\": [\"11980910\", \"12384504\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context of HNF1\\u03b1 phosphorylation not established\", \"Stoichiometry of p38 sequestration unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined DYRK1B as a Rho-GTPase-induced driver of myoblast differentiation and a brake on cell migration/invasion regulated by the Met adaptor RanBPM, linking it to both differentiation and motility control.\",\n      \"evidence\": \"Constitutively active GTPase expression, siRNA with differentiation markers, yeast two-hybrid/Co-IP and migration assays\",\n      \"pmids\": [\"12902328\", \"14500717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct substrates driving fusion not identified at this stage\", \"How RanBPM inhibits kinase activity unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Established the core quiescence mechanism: DYRK1B directly phosphorylates p27Kip1 (Ser10) to stabilize it, phosphorylates cyclin D1 to destabilize it, and phosphorylates class II HDACs to relieve MEF2-driven myogenesis, converting earlier correlative survival/differentiation roles into defined substrate-level events.\",\n      \"evidence\": \"In vitro kinase assays, phospho-site mutagenesis, RNAi, and reporter/localization assays\",\n      \"pmids\": [\"15010468\", \"15075324\", \"15546868\", \"12455049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact cyclin D1 site (Thr286 vs Thr288) later revised\", \"How a single kinase coordinates opposite stabilizing/destabilizing outcomes unexplained\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Extended the survival program to p21Cip1: DYRK1B phosphorylates p21 at Ser153 to drive cytoplasmic relocalization where it blocks caspase-3, and traced upstream activation to a Rac1\\u2192MKK3 cascade engaged by E-cadherin ligation.\",\n      \"evidence\": \"Phosphomimetic mutants, GFP-p21 localization, caspase assays, dominant-negative Rac1/MKK3 and kinase activity assays\",\n      \"pmids\": [\"15851482\", \"16257974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous trigger of the survival pathway in tumors not defined\", \"Link between cell contact and kinase activation incompletely mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected DYRK1B to oncogenic transformation by showing K-RAS activates it through Rac1\\u2192MKK3 in pancreatic cancer, establishing it as a RAS effector relevant to therapy.\",\n      \"evidence\": \"Multiple independent RNAi sequences, dominant-negative K-ras, Rac1 inhibitor, kinase activity assays\",\n      \"pmids\": [\"17671193\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RAS-driven quiescence is reversible therapeutically not addressed\", \"Downstream effectors in tumors not fully enumerated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linked apoptotic machinery to quiescence control, showing BCL2/BCL-xL stabilize p27 via MIRK-mediated Ser10 phosphorylation in a BAX/BAK-dependent manner.\",\n      \"evidence\": \"bax\\u2212/\\u2212bak\\u2212/\\u2212 knockout cells with BAX re-expression and phospho-specific p27 immunoblotting\",\n      \"pmids\": [\"18818203\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between BAX/BAK and MIRK activity unresolved\", \"Single lab/genetic system\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the survival mechanism of quiescent tumor cells: DYRK1B upregulates antioxidant genes (SOD2, SOD3, ferroxidase) to lower ROS, with ectopic antioxidant rescue confirming causality.\",\n      \"evidence\": \"Inducible shRNA, ROS measurement, antioxidant gene expression, and ectopic-expression rescue\",\n      \"pmids\": [\"19351855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional mechanism for antioxidant gene induction not defined\", \"Direct substrate mediating gene expression unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Consolidated the quiescence cell-cycle model (cyclin D1/D3 destabilization maintaining G0) and connected DYRK1B to Hedgehog pathway antagonism downstream of mutant RAS.\",\n      \"evidence\": \"RNAi, cyclin D1-T288A rescue, CDK4/p130 readouts, and Gli2/Gli3 processing assays\",\n      \"pmids\": [\"19542220\", \"20512148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of HH antagonism only partially defined\", \"How quiescence couples to paracrine HH redirection unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified CIRP as a substrate-selective regulator that binds DYRK1B and uncouples its p27 versus cyclin D1 activities, revealing combinatorial control of the quiescence program.\",\n      \"evidence\": \"Co-IP, siRNA, stability assays, and co-localization in spermatogonia\",\n      \"pmids\": [\"22711815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of substrate-selective inhibition unknown\", \"Physiological role in spermatogonia not fully tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linked DYRK1B to human disease and metabolism: a gain-of-function R102C allele causes a monogenic syndrome of obesity and diabetes, enhancing adipogenesis, suppressing SHH/Wnt, and promoting gluconeogenic gene expression; selective inhibitor and MS work corrected the cyclin D1 site to Thr286 (GSK3\\u03b2-independent) and CREB was shown to drive MIRK transcription upon mTOR inhibition.\",\n      \"evidence\": \"Patient-derived cells and reporter assays; AZ191 inhibitor with MS phospho-mapping; CREB ChIP/reporter and siRNA\",\n      \"pmids\": [\"24827035\", \"24134204\", \"24590896\", \"24955215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism converting R102C to gain-of-function not yet defined here\", \"How adipogenic and cell-cycle roles integrate metabolically unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined DYRK1B activation biochemistry\\u2014cis-autophosphorylation on Y273 during translation plus ERK2-mediated and trans-autophosphorylation at S421 contributing to activity\\u2014and added NKX3.1 (Ser185) as a degradation substrate.\",\n      \"evidence\": \"In vitro kinase assays with recombinant ERK2, kinase-dead mutants, KRAS(G12V), Co-IP and phospho-site mutagenesis\",\n      \"pmids\": [\"26346493\", \"25777618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each phospho-input in vivo not quantified\", \"Structural basis of co-translational maturation not yet resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Mechanistically explained disease alleles and expanded Hedgehog signaling roles: DH-box mutations (H90P/R102C) impair chaperone-dependent maturation causing cytoplasmic aggregates, and DYRK1B mediates Hh-induced mTOR/AKT activation with dual feedback on GLI.\",\n      \"evidence\": \"Detergent fractionation, phospho-tyrosine immunoblot, CDC37 Co-IP, HSP90 inhibitor sensitivity; Hh stimulation with AKT/mTOR readouts\",\n      \"pmids\": [\"28743892\", \"27903983\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Aggregation phenotype not linked to in vivo disease tissue\", \"Direct DYRK1B substrate in Hh\\u2192mTOR axis unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established cytoskeletal and chaperone-network roles: DYRK1B phosphorylates GSK3\\u03b2-Ser9 to suppress HDAC6 and increase microtubule acetylation, and WDR68/DCAF7 is required for DYRK1B protein stabilization/maturation.\",\n      \"evidence\": \"Phospho-specific immunoblots, HDAC6 activity and migration assays; WDR68 knockout cells with proteasome controls\",\n      \"pmids\": [\"30317528\", \"30496304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect GSK3\\u03b2 phosphorylation not fully isolated\", \"Molecular role of WDR68 in maturation undefined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed a genome-protection function: DYRK1B is recruited to DNA double-strand breaks and phosphorylates EHMT2 to enforce DSB-induced transcriptional silencing and efficient repair, a role distinct from its cell-cycle/metabolic functions.\",\n      \"evidence\": \"Kinome chemical screen, laser micro-irradiation with live imaging, kinase-dead/knockout, EHMT2 phosphorylation and transcription-rescue assays\",\n      \"pmids\": [\"32611815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Recruitment mechanism to break sites not defined\", \"Full DSB substrate set beyond EHMT2 unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended the DSB role to the nucleolus (rDNA transcription suppression and repair, ATM-uncoupled) and identified 4E-BP1/autophagy as a muscle-differentiation effector disrupted by the R102C disease allele.\",\n      \"evidence\": \"Targeted rDNA DSBs with micro-irradiation and rDNA copy-number assays; proteomics, zebrafish CRISPR knockout, autophagy-flux rescue\",\n      \"pmids\": [\"33469661\", \"34752933\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nucleolar substrate(s) for rDNA suppression not identified\", \"Whether DSB and metabolic functions are mechanistically linked unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined major disease-driving outputs: kinase-independent mTORC2 activation drives hepatic lipogenesis and NASH (rescued by mTORC2 disruption), STAT3 binding amplifies cardiac/inflammatory signaling, and species-divergent C-lobe sequences explain DYRK1B's poor in vitro maturation.\",\n      \"evidence\": \"Liver AAV overexpression with genetic mTORC2 rescue; transgenic/KO TAC hearts with STAT3 Co-IP; bacterial cell-free autophosphorylation and thermal-stability assays\",\n      \"pmids\": [\"34855620\", \"35235343\", \"35165364\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a kinase activates mTORC2 without catalysis unresolved\", \"Direct binding interface with STAT3 not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified FOXO1 (Ser329) phosphorylation controlling its localization as the basis for DYRK1B's role in CD4+ T-cell fate, balancing Treg versus Th1/Th17 differentiation.\",\n      \"evidence\": \"DYRK1B inhibitor treatment, FOXO1 phospho-specific assays, T-cell differentiation FACS and murine CHS model\",\n      \"pmids\": [\"37120440\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Site Ser329 vs later-reported Thr467/Ser468 reconciliation needed\", \"Direct vs indirect phosphorylation not fully isolated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded the cancer and metabolic roles: DYRK1B suppresses the CD24 'don't eat me' signal to evade macrophage phagocytosis in pancreatic cancer, and promotes WBP2 ubiquitin-dependent degradation to impair hepatic insulin signaling.\",\n      \"evidence\": \"Autochthonous/transplant PDAC models with genetic and pharmacological loss, phagocytosis assays; mouse overexpression/KO, proteomics, ubiquitylation and WBP2 rescue\",\n      \"pmids\": [\"38834297\", \"39296215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking DYRK1B activity to CD24 surface levels undefined\", \"Whether WBP2 degradation requires direct phosphorylation unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Mature mechanistic synthesis: defined FOXO1 Thr467/Ser468 phosphorylation driving hepatic gluconeogenesis (with liver cKO protection), resolved CMGC-insert/proline-dependent maturation and disease variant R349W effects, solved the AZ191-bound crystal structure explaining selectivity, and linked DYRK1B/STAT3 to inflammatory resolution.\",\n      \"evidence\": \"In vivo/in vitro kinase assays with liver cKO; domain swaps and point mutants; X-ray crystallography; small-molecule inhibitor inflammation models\",\n      \"pmids\": [\"40287828\", \"41444824\", \"41061777\", \"39985685\", \"41888523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the diverse substrate repertoire is selected in different tissues remains unresolved\", \"RFX7 negative-feedback role's physiological significance not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how a single kinase coordinates its opposing kinase-dependent (substrate phosphorylation) and kinase-independent (mTORC2 activation) outputs and selects among its many substrates across muscle, cancer, immune, and metabolic contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified model for tissue-specific substrate selection\", \"Kinase-independent scaffolding mechanism for mTORC2 undefined\", \"Recruitment determinants to DSB/nucleolar sites unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [7, 8, 9, 10, 23, 28, 36]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [7, 8, 19, 22, 36]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 9, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [30, 35]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 7, 17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10, 21, 25]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [29]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [7, 16, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 9]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [28, 29]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 12, 24, 31]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [30, 36, 40]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [6, 8, 23]}\n    ],\n    \"complexes\": [\n      \"mTORC2\",\n      \"MIRK\\u2013DCoHm\\u2013HNF1\\u03b1 complex\"\n    ],\n    \"partners\": [\n      \"MKK3\",\n      \"RanBPM\",\n      \"STAT3\",\n      \"RFX7\",\n      \"CIRP\",\n      \"WDR68\",\n      \"CDC37\",\n      \"NKX3.1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":7,"faith_pct":85.71428571428571}}